CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | enol |
|
Accession: | CHEBI:33823
|
browse the term
|
Definition: | Alkenols; the term refers specifically to vinylic alcohols, which have the structure HOCR'=CR2. Enols are tautomeric with aldehydes (R' = H) or ketones (R' =/= H). |
Synonyms: | related_synonym: | Formula=C2HOR3; SMILES=OC(=C(*)*)*; alkenols; enols |
| cyclic_relationship: | is_conjugate_acid_of CHEBI:142839 |
|
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
andrastin A results in increased expression of and results in increased secretion of CSF2 protein |
CTD |
PMID:28535995 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
andrastin A results in increased expression of and results in increased secretion of TGFB1 protein |
CTD |
PMID:28535995 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
andrastin A results in increased expression of and results in increased secretion of TNF protein |
CTD |
PMID:28535995 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Becn1 |
beclin 1 |
increases expression |
ISO |
beta-thujaplicin results in increased expression of BECN1 protein |
CTD |
PMID:25044443 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
beta-thujaplicin results in decreased phosphorylation of MTOR protein |
CTD |
PMID:25044443 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation |
ISO |
beta-thujaplicin results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:25044443 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression |
ISO |
beta-thujaplicin results in decreased expression of SQSTM1 protein |
CTD |
PMID:25044443 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
brazilein results in decreased expression of CCND1 mRNA; brazilein results in decreased expression of CCND1 protein |
CTD |
PMID:23948132 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
ISO |
brazilein results in decreased expression of CTNNB1 protein |
CTD |
PMID:23948132 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases expression |
ISO |
brazilein results in decreased expression of GSK3B protein modified form |
CTD |
PMID:23948132 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression |
ISO |
brazilein promotes the reaction [SB 203580 results in decreased expression of and results in decreased activity of MMP2 protein]; brazilein promotes the reaction [wortmannin results in decreased expression of and results in decreased activity of MMP2 protein]; brazilein results in decreased expression of and results in decreased activity of MMP2 protein; SB 203580 promotes the reaction [brazilein results in decreased expression of and results in decreased activity of MMP2 protein]; wortmannin promotes the reaction [brazilein results in decreased expression of and results in decreased activity of MMP2 protein] brazilein results in decreased expression of MMP2 mRNA |
CTD |
PMID:23707804 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
brazilein results in decreased expression of and results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:23707804 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases expression |
ISO |
brazilein results in decreased expression of RELA protein |
CTD |
PMID:23707804 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
[Biotin co-treated with coenzyme Q10] inhibits the reaction [Aluminum Chloride results in decreased phosphorylation of AKT1 protein]; [Biotin co-treated with coenzyme Q10] inhibits the reaction [Aluminum Chloride results in increased cleavage of AKT1 protein]; coenzyme Q10 inhibits the reaction [Aluminum Chloride results in decreased phosphorylation of AKT1 protein]; coenzyme Q10 inhibits the reaction [Aluminum Chloride results in increased cleavage of AKT1 protein]; coenzyme Q10 inhibits the reaction [Atorvastatin results in decreased phosphorylation of AKT1 protein]; coenzyme Q10 inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:27087047 PMID:27345130 PMID:32383521 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions |
ISO |
[coenzyme Q10 co-treated with TNFSF11 protein] results in increased expression of APAF1 mRNA; [coenzyme Q10 co-treated with TNFSF11 protein] results in increased expression of APAF1 protein |
CTD |
PMID:33754447 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions decreases response to substance |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [coenzyme Q10 results in decreased susceptibility to APP protein]; [Biotin co-treated with coenzyme Q10] inhibits the reaction [Aluminum Chloride results in increased expression of APP protein]; coenzyme Q10 inhibits the reaction [Aluminum Chloride results in increased expression of APP protein]; coenzyme Q10 inhibits the reaction [APP protein results in decreased expression of PIK3R1 protein]; coenzyme Q10 inhibits the reaction [APP protein results in decreased phosphorylation of GSK3B protein]; coenzyme Q10 inhibits the reaction [APP protein results in increased cleavage of CASP3 protein] |
CTD |
PMID:22186599 PMID:32383521 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arap2 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 |
multiple interactions |
ISO |
coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of ARAP2 mRNA] |
CTD |
PMID:21370964 |
|
NCBI chr14:46,717,657...46,917,326
Ensembl chr14:46,718,760...46,917,154
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Doxorubicin results in decreased phosphorylation of BAD protein] |
CTD |
PMID:27087047 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Doxorubicin results in increased expression of BAK1 protein] |
CTD |
PMID:27087047 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP ISO |
[epigallocatechin gallate co-treated with coenzyme Q10] inhibits the reaction [Cisplatin results in increased expression of BAX protein]; coenzyme Q10 inhibits the reaction [Doxorubicin results in increased expression of BAX protein]; coenzyme Q10 inhibits the reaction [lead acetate results in increased expression of BAX mRNA]; coenzyme Q10 inhibits the reaction [lead acetate results in increased expression of BAX protein] [coenzyme Q10 co-treated with TNFSF11 protein] results in increased expression of BAX mRNA; [coenzyme Q10 co-treated with TNFSF11 protein] results in increased expression of BAX protein; coenzyme Q10 inhibits the reaction [bisphenol A results in increased expression of BAX mRNA] |
CTD |
PMID:27087047 PMID:32116774 PMID:33393703 PMID:33754447 PMID:34186417 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions |
EXP ISO |
coenzyme Q10 results in increased expression of BCL2 mRNA [coenzyme Q10 co-treated with TNFSF11 protein] results in decreased expression of BCL2 mRNA; [coenzyme Q10 co-treated with TNFSF11 protein] results in decreased expression of BCL2 protein; coenzyme Q10 inhibits the reaction [bisphenol A results in decreased expression of BCL2 mRNA] [epigallocatechin gallate co-treated with coenzyme Q10] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; coenzyme Q10 inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; coenzyme Q10 inhibits the reaction [lead acetate results in decreased expression of BCL2 mRNA]; coenzyme Q10 inhibits the reaction [lead acetate results in decreased expression of BCL2 protein] |
CTD |
PMID:18817789 PMID:27087047 PMID:32116774 PMID:33393703 PMID:33754447 PMID:34186417 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Doxorubicin results in decreased expression of BCL2L1 protein] |
CTD |
PMID:27087047 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
C1qa |
complement C1q A chain |
decreases expression |
ISO |
coenzyme Q10 results in decreased expression of C1QA mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534
|
|
G |
C4b |
complement C4B (Chido blood group) |
decreases expression |
ISO |
coenzyme Q10 results in decreased expression of C4B mRNA |
CTD |
PMID:19555370 |
|
NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
[epigallocatechin gallate co-treated with coenzyme Q10] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; coenzyme Q10 inhibits the reaction [APP protein results in increased cleavage of CASP3 protein]; coenzyme Q10 inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; coenzyme Q10 inhibits the reaction [lead acetate results in increased activity of CASP3 protein]; coenzyme Q10 inhibits the reaction [lead acetate results in increased expression of CASP3 mRNA]; coenzyme Q10 inhibits the reaction [Vincristine results in increased expression of CASP3 protein] [coenzyme Q10 co-treated with TNFSF11 protein] results in increased cleavage of CASP3 protein; coenzyme Q10 inhibits the reaction [bisphenol A results in increased expression of CASP3 mRNA]; coenzyme Q10 inhibits the reaction [Cisplatin results in increased expression of CASP3 protein] |
CTD |
PMID:20510337 PMID:22186599 PMID:27087047 PMID:32116774 PMID:33393703 PMID:33754447 PMID:34186417 PMID:34939713 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Doxorubicin results in increased expression of CASP8 protein] |
CTD |
PMID:27087047 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Doxorubicin results in increased expression of CASP9 protein] |
CTD |
PMID:27087047 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
[epigallocatechin gallate co-treated with coenzyme Q10] inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; [Quercetin co-treated with coenzyme Q10] inhibits the reaction [Streptozocin results in increased activity of CAT protein]; [Vitamin E co-treated with coenzyme Q10] inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; [Vitamin E co-treated with coenzyme Q10] results in increased activity of CAT protein; coenzyme Q10 inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; coenzyme Q10 inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; coenzyme Q10 inhibits the reaction [Dichlorvos results in decreased activity of CAT protein]; coenzyme Q10 inhibits the reaction [lead acetate results in decreased activity of CAT protein]; coenzyme Q10 inhibits the reaction [lead acetate results in decreased expression of CAT mRNA] [coenzyme Q10 co-treated with TNFSF11 protein] affects the activity of CAT protein; [Vitamin E co-treated with coenzyme Q10] inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; coenzyme Q10 affects the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] affects the activity of CAT protein]; coenzyme Q10 promotes the reaction [Acetaminophen results in increased expression of CAT mRNA] |
CTD |
PMID:12242689 PMID:19958828 PMID:25382014 PMID:29143438 PMID:29948670 PMID:32116774 PMID:33271250 PMID:33754447 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Doxorubicin results in increased expression of CCN2 protein] |
CTD |
PMID:27087047 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
coenzyme Q10 results in increased expression of CCND1 protein |
CTD |
PMID:34668565 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Doxorubicin results in increased expression of COL1A1 protein] |
CTD |
PMID:27087047 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
coenzyme Q10 inhibits the reaction [Acetaminophen affects the phosphorylation of and affects the localization of CTNNB1 protein] |
CTD |
PMID:34668565 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
coenzyme Q10 inhibits the reaction [bisphenol A results in increased expression of and affects the localization of CTSB protein]; coenzyme Q10 inhibits the reaction [bisphenol A results in increased expression of CTSB mRNA] |
CTD |
PMID:34186417 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
ISO |
coenzyme Q10 inhibits the reaction [bisphenol A results in increased expression of and affects the localization of CTSD protein]; coenzyme Q10 inhibits the reaction [bisphenol A results in increased expression of CTSD mRNA] |
CTD |
PMID:34186417 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctss |
cathepsin S |
decreases expression |
ISO |
coenzyme Q10 results in decreased expression of CTSS mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [lead acetate results in increased expression of CYCS mRNA] |
CTD |
PMID:33856607 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
coenzyme Q10 inhibits the reaction [Lamivudine results in increased secretion of EDN1 protein]; coenzyme Q10 inhibits the reaction [Tenofovir results in increased secretion of EDN1 protein]; coenzyme Q10 inhibits the reaction [Zidovudine results in increased secretion of EDN1 protein] |
CTD |
PMID:23640862 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Eps15 |
epidermal growth factor receptor pathway substrate 15 |
multiple interactions |
ISO |
coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of EPS15 mRNA] |
CTD |
PMID:21370964 |
|
NCBI chr 5:124,045,865...124,146,221
Ensembl chr 5:124,045,926...124,146,221
|
|
G |
Etv3 |
ETS variant transcription factor 3 |
multiple interactions |
ISO |
coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of ETV3 mRNA] |
CTD |
PMID:21370964 |
|
NCBI chr 2:172,965,461...172,980,320
Ensembl chr 2:172,965,588...172,980,314
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Doxorubicin results in increased expression of FADD protein] |
CTD |
PMID:27087047 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Doxorubicin results in increased expression of FASLG protein] |
CTD |
PMID:27087047 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased expression of FSHR mRNA] |
CTD |
PMID:31557371 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
[Taurine co-treated with coenzyme Q10] inhibits the reaction [Chlorpromazine results in decreased activity of G6PD protein]; [Taurine co-treated with coenzyme Q10] results in increased activity of G6PD protein; coenzyme Q10 inhibits the reaction [Chlorpromazine results in decreased activity of G6PD protein] |
CTD |
PMID:33548410 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression multiple interactions |
ISO EXP |
coenzyme Q10 results in decreased expression of GFAP mRNA [Oxygen co-treated with coenzyme Q10] results in decreased expression of GFAP protein |
CTD |
PMID:19555370 PMID:35212449 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GGT1 protein] |
CTD |
PMID:27387968 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GOT1 protein] |
CTD |
PMID:27387968 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
[epigallocatechin gallate co-treated with coenzyme Q10] inhibits the reaction [Cisplatin results in increased activity of GPT protein]; coenzyme Q10 inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GPT protein]; coenzyme Q10 inhibits the reaction [sodium arsenite results in increased expression of GPT protein] Chloroquine inhibits the reaction [coenzyme Q10 inhibits the reaction [Acetaminophen results in increased activity of GPT protein]]; coenzyme Q10 inhibits the reaction [Acetaminophen results in increased activity of GPT protein] |
CTD |
PMID:27174133 PMID:27387968 PMID:33271250 PMID:33393703 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO EXP |
coenzyme Q10 promotes the reaction [Acetaminophen results in increased expression of GPX1 mRNA] coenzyme Q10 inhibits the reaction [lead acetate results in decreased expression of GPX1 mRNA] |
CTD |
PMID:32116774 PMID:33271250 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP ISO |
coenzyme Q10 inhibits the reaction [APP protein results in decreased phosphorylation of GSK3B protein] coenzyme Q10 promotes the reaction [Acetaminophen results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:22186599 PMID:34668565 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions increases expression |
EXP |
[epigallocatechin gallate co-treated with coenzyme Q10] inhibits the reaction [Cisplatin results in decreased activity of GSR protein]; [Vitamin E co-treated with coenzyme Q10] inhibits the reaction [Cadmium Chloride results in decreased activity of GSR protein]; [Vitamin E co-treated with coenzyme Q10] results in increased activity of GSR protein; coenzyme Q10 inhibits the reaction [Cadmium Chloride results in decreased activity of GSR protein]; coenzyme Q10 inhibits the reaction [lead acetate results in decreased activity of GSR protein]; coenzyme Q10 inhibits the reaction [lead acetate results in decreased expression of GSR mRNA] coenzyme Q10 results in increased expression of GSR mRNA |
CTD |
PMID:19958828 PMID:32116774 PMID:33393703 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [lead acetate results in increased expression of HMOX1 mRNA]; coenzyme Q10 inhibits the reaction [lead acetate results in increased expression of HMOX1 protein]; coenzyme Q10 inhibits the reaction [sodium arsenite results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:27174133 PMID:32116774 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
ISO EXP |
[Valproic Acid co-treated with coenzyme Q10] inhibits the reaction [Benzene results in increased expression of IL10 protein] coenzyme Q10 results in increased expression of IL10 mRNA; coenzyme Q10 results in increased expression of IL10 protein coenzyme Q10 inhibits the reaction [lead acetate results in decreased expression of IL10 mRNA]; coenzyme Q10 inhibits the reaction [lead acetate results in decreased expression of IL10 protein] |
CTD |
PMID:32116774 PMID:35090963 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[Biotin co-treated with coenzyme Q10] inhibits the reaction [Aluminum Chloride results in increased expression of IL1B protein]; coenzyme Q10 inhibits the reaction [Aluminum Chloride results in increased expression of IL1B protein]; coenzyme Q10 inhibits the reaction [lead acetate results in increased expression of IL1B mRNA]; coenzyme Q10 inhibits the reaction [lead acetate results in increased expression of IL1B protein]; coenzyme Q10 inhibits the reaction [Vincristine results in increased expression of IL1B protein] |
CTD |
PMID:32116774 PMID:32383521 PMID:34939713 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
[Biotin co-treated with coenzyme Q10] inhibits the reaction [Aluminum Chloride results in increased expression of IL6 protein]; coenzyme Q10 inhibits the reaction [Aluminum Chloride results in increased expression of IL6 protein] |
CTD |
PMID:32383521 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
EXP |
[Biotin co-treated with coenzyme Q10] inhibits the reaction [Aluminum Chloride affects the phosphorylation of IRS1 protein]; coenzyme Q10 inhibits the reaction [Aluminum Chloride affects the phosphorylation of IRS1 protein] |
CTD |
PMID:32383521 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Kcnj6 |
potassium inwardly-rectifying channel, subfamily J, member 6 |
decreases abundance |
ISO |
KCNJ6 gene mutant form results in decreased abundance of coenzyme Q10 |
CTD |
PMID:15256069 |
|
NCBI chr11:34,061,702...34,308,758
Ensembl chr11:34,061,708...34,308,758
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
multiple interactions |
ISO |
coenzyme Q10 inhibits the reaction [bisphenol A results in decreased expression of LAMP2 protein] |
CTD |
PMID:34186417 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Ldhc |
lactate dehydrogenase C |
multiple interactions increases activity |
EXP |
[Taurine co-treated with coenzyme Q10] inhibits the reaction [Chlorpromazine results in decreased activity of LDHC protein]; [Taurine co-treated with coenzyme Q10] results in increased activity of LDHC protein; coenzyme Q10 inhibits the reaction [Chlorpromazine results in decreased activity of LDHC protein] coenzyme Q10 results in increased activity of LDHC protein |
CTD |
PMID:33548410 |
|
NCBI chr 1:97,385,984...97,403,382
Ensembl chr 1:97,382,379...97,403,378
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein] |
CTD |
PMID:27087047 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Doxorubicin results in increased expression of MMP9 protein] |
CTD |
PMID:27087047 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mt3 |
metallothionein 3 |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [lead acetate results in decreased expression of MT3 mRNA]; coenzyme Q10 inhibits the reaction [lead acetate results in decreased expression of MT3 protein] |
CTD |
PMID:33856607 |
|
NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of NCOA2 mRNA] |
CTD |
PMID:21370964 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Ndufb6 |
NADH:ubiquinone oxidoreductase subunit B6 |
increases expression multiple interactions |
ISO |
coenzyme Q10 results in increased expression of NDUFB6 protein coenzyme Q10 inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA] |
CTD |
PMID:19523936 |
|
NCBI chr 5:55,400,543...55,410,110
Ensembl chr 5:55,400,543...55,410,181
|
|
G |
Ndufs7 |
NADH:ubiquinone oxidoreductase core subunit S7 |
increases expression |
ISO |
coenzyme Q10 results in increased expression of NDUFS7 protein |
CTD |
PMID:19523936 |
|
NCBI chr 7:9,452,556...9,460,135
Ensembl chr 7:9,450,392...9,460,195
|
|
G |
Nefl |
neurofilament light chain |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Vincristine results in increased expression of NEFL protein] |
CTD |
PMID:34939713 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
[coenzyme Q10 co-treated with TNFSF11 protein] affects the expression of NFATC1 mRNA; [coenzyme Q10 co-treated with TNFSF11 protein] affects the expression of NFATC1 protein; coenzyme Q10 affects the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] affects the expression of NFATC1 mRNA]; coenzyme Q10 affects the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] affects the expression of NFATC1 protein] |
CTD |
PMID:33754447 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression |
EXP ISO |
coenzyme Q10 inhibits the reaction [lead acetate affects the localization of NFE2L2 protein]; coenzyme Q10 inhibits the reaction [lead acetate results in decreased expression of NFE2L2 mRNA]; coenzyme Q10 inhibits the reaction [sodium arsenite results in decreased expression of NFE2L2 mRNA]; coenzyme Q10 inhibits the reaction [Vincristine results in decreased expression of NFE2L2 mRNA] coenzyme Q10 results in increased expression of NFE2L2 mRNA coenzyme Q10 promotes the reaction [Acetaminophen results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:27174133 PMID:32116774 PMID:33271250 PMID:34939713 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
coenzyme Q10 inhibits the reaction [Cisplatin results in increased expression of NOS2 protein] coenzyme Q10 inhibits the reaction [lead acetate results in increased expression of NOS2 mRNA] |
CTD |
PMID:20510337 PMID:32116774 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
coenzyme Q10 inhibits the reaction [Lamivudine results in decreased phosphorylation of NOS3 protein]; coenzyme Q10 inhibits the reaction [Tenofovir results in decreased phosphorylation of NOS3 protein]; coenzyme Q10 inhibits the reaction [Zidovudine results in decreased phosphorylation of NOS3 protein] |
CTD |
PMID:23640862 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Oscar |
osteoclast associated Ig-like receptor |
multiple interactions |
ISO |
[coenzyme Q10 co-treated with TNFSF11 protein] affects the expression of OSCAR mRNA; [coenzyme Q10 co-treated with TNFSF11 protein] affects the expression of OSCAR protein; coenzyme Q10 affects the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] affects the expression of OSCAR mRNA]; coenzyme Q10 affects the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] affects the expression of OSCAR protein] |
CTD |
PMID:33754447 |
|
NCBI chr 1:65,607,214...65,615,395
Ensembl chr 1:65,607,410...65,613,758
|
|
G |
Pah |
phenylalanine hydroxylase |
decreases expression |
ISO |
coenzyme Q10 results in decreased expression of PAH mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions increases expression |
ISO |
coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased expression of PCNA mRNA] coenzyme Q10 results in increased expression of PCNA protein |
CTD |
PMID:31557371 PMID:34668565 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [APP protein results in decreased expression of PIK3R1 protein] |
CTD |
PMID:22186599 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Pink1 |
PTEN induced kinase 1 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [coenzyme Q10 promotes the reaction [Acetaminophen results in increased expression of PINK1 protein]]; coenzyme Q10 promotes the reaction [Acetaminophen results in increased expression of PINK1 protein] |
CTD |
PMID:33271250 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Pou2f1 |
POU class 2 homeobox 1 |
multiple interactions |
ISO |
coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of POU2F1 mRNA] |
CTD |
PMID:21370964 |
|
NCBI chr13:78,120,617...78,263,306
Ensembl chr13:78,130,685...78,263,363
|
|
G |
Ppp2r5c |
protein phosphatase 2, regulatory subunit B', gamma |
multiple interactions |
ISO |
coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of PPP2R5C mRNA] |
CTD |
PMID:21370964 |
|
NCBI chr 6:129,461,689...129,598,344
Ensembl chr 6:129,461,648...129,598,346
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [coenzyme Q10 promotes the reaction [Acetaminophen results in increased expression of PRKN protein]]; coenzyme Q10 promotes the reaction [Acetaminophen results in increased expression of PRKN protein] |
CTD |
PMID:33271250 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Psd3 |
pleckstrin and Sec7 domain containing 3 |
multiple interactions |
ISO |
coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of PSD3 mRNA] |
CTD |
PMID:21370964 |
|
NCBI chr16:21,465,643...22,035,846
Ensembl chr16:21,465,639...22,034,547
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Vincristine results in increased expression of RELA protein] |
CTD |
PMID:34939713 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sarm1 |
sterile alpha and TIR motif containing 1 |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Vincristine results in increased expression of SARM1 mRNA] |
CTD |
PMID:34939713 |
|
NCBI chr10:63,369,456...63,393,016
Ensembl chr10:63,369,456...63,392,822
|
|
G |
Skap2 |
src kinase associated phosphoprotein 2 |
decreases expression |
ISO |
coenzyme Q10 results in decreased expression of SKAP2 mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 4:80,948,832...81,100,900
Ensembl chr 4:80,950,580...81,100,891
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [sodium arsenite results in increased expression of SMAD3 mRNA] |
CTD |
PMID:27174133 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO EXP |
coenzyme Q10 inhibits the reaction [1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline results in increased expression of SNCA protein] coenzyme Q10 inhibits the reaction [Dichlorvos promotes the reaction [SNCA protein binds to SNCA protein]] [coenzyme Q10 co-treated with Creatine] results in decreased expression of SNCA protein |
CTD |
PMID:15114628 PMID:19476553 PMID:21843543 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Sod2 |
superoxide dismutase 2 |
affects expression increases expression multiple interactions |
EXP ISO |
coenzyme Q10 affects the expression of SOD2 protein coenzyme Q10 results in increased expression of SOD2 mRNA coenzyme Q10 inhibits the reaction [lead acetate results in decreased expression of SOD2 mRNA] coenzyme Q10 promotes the reaction [Acetaminophen results in increased expression of SOD2 mRNA] coenzyme Q10 inhibits the reaction [Acrolein results in increased expression of SOD2 protein] |
CTD |
PMID:22083459 PMID:24008411 PMID:32116774 PMID:33271250 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [coenzyme Q10 promotes the reaction [Acetaminophen results in decreased expression of SQSTM1 protein]]; coenzyme Q10 promotes the reaction [Acetaminophen results in decreased expression of SQSTM1 protein] |
CTD |
PMID:33271250 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
coenzyme Q10 inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]; coenzyme Q10 inhibits the reaction [sodium arsenite results in increased expression of TGFB1 mRNA] |
CTD |
PMID:27087047 PMID:27174133 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
coenzyme Q10 inhibits the reaction [Cisplatin results in increased expression of TNF protein] [Biotin co-treated with coenzyme Q10] inhibits the reaction [Aluminum Chloride results in increased expression of TNF protein]; coenzyme Q10 inhibits the reaction [Aluminum Chloride results in increased expression of TNF protein]; coenzyme Q10 inhibits the reaction [lead acetate results in increased expression of TNF mRNA]; coenzyme Q10 inhibits the reaction [lead acetate results in increased expression of TNF protein]; coenzyme Q10 inhibits the reaction [Vincristine results in increased expression of TNF protein] |
CTD |
PMID:20510337 PMID:32116774 PMID:32383521 PMID:34939713 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
[coenzyme Q10 co-treated with TNFSF11 protein] affects the activity of CAT protein; [coenzyme Q10 co-treated with TNFSF11 protein] affects the expression of NFATC1 mRNA; [coenzyme Q10 co-treated with TNFSF11 protein] affects the expression of NFATC1 protein; [coenzyme Q10 co-treated with TNFSF11 protein] affects the expression of OSCAR mRNA; [coenzyme Q10 co-treated with TNFSF11 protein] affects the expression of OSCAR protein; [coenzyme Q10 co-treated with TNFSF11 protein] affects the expression of TRAF2 mRNA; [coenzyme Q10 co-treated with TNFSF11 protein] affects the expression of TRAF2 protein; [coenzyme Q10 co-treated with TNFSF11 protein] results in decreased expression of BCL2 mRNA; [coenzyme Q10 co-treated with TNFSF11 protein] results in decreased expression of BCL2 protein; [coenzyme Q10 co-treated with TNFSF11 protein] results in increased cleavage of CASP3 protein; [coenzyme Q10 co-treated with TNFSF11 protein] results in increased expression of APAF1 mRNA; [coenzyme Q10 co-treated with TNFSF11 protein] results in increased expression of APAF1 protein; [coenzyme Q10 co-treated with TNFSF11 protein] results in increased expression of BAX mRNA; [coenzyme Q10 co-treated with TNFSF11 protein] results in increased expression of BAX protein; coenzyme Q10 affects the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] affects the activity of CAT protein]; coenzyme Q10 affects the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] affects the expression of NFATC1 mRNA]; coenzyme Q10 affects the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] affects the expression of NFATC1 protein]; coenzyme Q10 affects the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] affects the expression of OSCAR mRNA]; coenzyme Q10 affects the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] affects the expression of OSCAR protein]; coenzyme Q10 affects the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] affects the expression of TRAF2 mRNA]; coenzyme Q10 affects the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] affects the expression of TRAF2 protein] |
CTD |
PMID:33754447 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO EXP |
coenzyme Q10 inhibits the reaction [Cisplatin results in increased expression of TRP53 protein] [epigallocatechin gallate co-treated with coenzyme Q10] inhibits the reaction [Cisplatin results in increased phosphorylation of TP53 protein] |
CTD |
PMID:20510337 PMID:33393703 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
multiple interactions |
ISO |
[coenzyme Q10 co-treated with TNFSF11 protein] affects the expression of TRAF2 mRNA; [coenzyme Q10 co-treated with TNFSF11 protein] affects the expression of TRAF2 protein; coenzyme Q10 affects the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] affects the expression of TRAF2 mRNA]; coenzyme Q10 affects the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] affects the expression of TRAF2 protein] |
CTD |
PMID:33754447 |
|
NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
|
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
decreases expression |
EXP |
aminochrome 1 results in decreased expression of AGTR2 mRNA |
CTD |
PMID:18522901 |
|
NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
EXP |
[aminochrome 1 co-treated with Dicumarol] results in increased activity of CASP3 protein aminochrome 1 results in increased activity of CASP3 protein |
CTD |
PMID:21427056 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
[aminochrome 1 co-treated with Dicumarol] affects the localization of CYCS protein |
CTD |
PMID:21427056 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
decreases expression |
EXP |
aminochrome 1 results in decreased expression of GDNF mRNA |
CTD |
PMID:29588162 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression |
EXP |
aminochrome 1 results in decreased expression of GFAP protein |
CTD |
PMID:29588162 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
EXP |
aminochrome 1 results in increased expression of IL1B mRNA; aminochrome 1 results in increased expression of IL1B protein |
CTD |
PMID:29588162 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Ngf |
nerve growth factor |
decreases expression |
EXP |
aminochrome 1 results in decreased expression of NGF mRNA |
CTD |
PMID:29588162 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
affects response to substance multiple interactions |
EXP ISO |
NQO1 protein affects the susceptibility to aminochrome 1 NQO1 protein inhibits the reaction [aminochrome 1 promotes the reaction [SNCA protein binds to SNCA protein]] |
CTD |
PMID:20849151 PMID:25634539 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
aminochrome 1 promotes the reaction [SNCA protein binds to SNCA protein]; NQO1 protein inhibits the reaction [aminochrome 1 promotes the reaction [SNCA protein binds to SNCA protein]] |
CTD |
PMID:25634539 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Th |
tyrosine hydroxylase |
decreases expression |
EXP |
aminochrome 1 results in decreased expression of TH protein |
CTD |
PMID:29588162 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
aminochrome 1 results in increased expression of TNF mRNA; aminochrome 1 results in increased expression of TNF protein |
CTD |
PMID:29588162 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
embelin results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:24694877 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Atg12 |
autophagy related 12 |
multiple interactions |
ISO |
embelin results in increased cleavage of [ATG12 protein binds to ATG5 protein] |
CTD |
PMID:28722333 |
|
NCBI chr18:39,452,247...39,462,424
Ensembl chr18:39,452,191...39,462,418
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
embelin results in increased cleavage of [ATG12 protein binds to ATG5 protein] |
CTD |
PMID:28722333 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
embelin results in increased expression of BAX protein |
CTD |
PMID:24694877 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
embelin results in decreased expression of BCL2 protein |
CTD |
PMID:24694877 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Becn1 |
beclin 1 |
increases expression |
ISO |
embelin results in increased expression of BECN1 protein |
CTD |
PMID:28722333 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases degradation |
ISO |
embelin results in increased cleavage of CASP3 protein 3-methyladenine promotes the reaction [embelin results in increased degradation of CASP3 protein] |
CTD |
PMID:24694877 PMID:28722333 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases degradation multiple interactions |
ISO |
embelin results in increased degradation of CASP9 protein 3-methyladenine promotes the reaction [embelin results in increased degradation of CASP9 protein] |
CTD |
PMID:28722333 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
embelin inhibits the reaction [Paraquat results in decreased expression of CAT protein] |
CTD |
PMID:32020686 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
embelin results in decreased expression of CCND1 protein |
CTD |
PMID:24694877 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
embelin results in increased expression of CDH1 protein |
CTD |
PMID:24694877 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
embelin results in decreased expression of CDK2 protein |
CTD |
PMID:24694877 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
decreases expression |
ISO |
embelin results in decreased expression of CDK6 protein |
CTD |
PMID:24694877 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Dffa |
DNA fragmentation factor subunit alpha |
increases cleavage |
ISO |
embelin results in increased cleavage of DFFA protein |
CTD |
PMID:28722333 |
|
NCBI chr 5:159,540,715...159,553,639
Ensembl chr 5:159,540,715...159,553,633
|
|
G |
Gli1 |
GLI family zinc finger 1 |
decreases expression |
ISO |
embelin results in decreased expression of GLI1 protein |
CTD |
PMID:24694877 |
|
NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251
|
|
G |
Gli2 |
GLI family zinc finger 2 |
decreases expression |
ISO |
embelin results in decreased expression of GLI2 protein |
CTD |
PMID:24694877 |
|
NCBI chr13:29,946,882...30,163,589
Ensembl chr13:29,946,809...30,163,574
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
embelin inhibits the reaction [Paraquat results in increased expression of IL1B protein] |
CTD |
PMID:32020686 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
embelin inhibits the reaction [Paraquat results in increased expression of IL6 protein] |
CTD |
PMID:32020686 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kdr |
kinase insert domain receptor |
decreases expression |
ISO |
embelin results in decreased expression of KDR protein |
CTD |
PMID:24694877 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
embelin results in decreased expression of MKI67 protein |
CTD |
PMID:24694877 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression |
ISO |
embelin results in decreased expression of MMP2 protein |
CTD |
PMID:24694877 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression |
ISO |
embelin results in decreased expression of MMP9 protein |
CTD |
PMID:24694877 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
embelin results in increased cleavage of PARP1 protein 3-methyladenine promotes the reaction [embelin results in increased cleavage of PARP1 protein] |
CTD |
PMID:24694877 PMID:28722333 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression |
ISO |
embelin results in decreased expression of PCNA protein |
CTD |
PMID:24694877 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
embelin results in decreased expression of PTGS2 protein |
CTD |
PMID:24694877 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
embelin inhibits the reaction [Paraquat results in increased phosphorylation of RELA protein] |
CTD |
PMID:32020686 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
decreases expression |
ISO |
embelin results in decreased expression of SNAI1 protein |
CTD |
PMID:24694877 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
decreases expression |
ISO |
embelin results in decreased expression of SNAI2 protein |
CTD |
PMID:24694877 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Sqstm1 |
sequestosome 1 |
increases degradation |
ISO |
embelin results in increased degradation of SQSTM1 protein |
CTD |
PMID:28722333 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
embelin inhibits the reaction [Paraquat results in increased expression of TNF protein] |
CTD |
PMID:32020686 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
increases expression |
ISO |
embelin results in increased expression of TNFRSF10A protein |
CTD |
PMID:24694877 |
|
NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
embelin results in decreased expression of VEGFA protein |
CTD |
PMID:24694877 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases activity increases degradation |
ISO |
embelin results in decreased activity of XIAP protein embelin results in increased degradation of XIAP protein |
CTD |
PMID:16339139 PMID:28722333 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
decreases expression |
ISO |
embelin results in decreased expression of ZEB1 protein |
CTD |
PMID:24694877 |
|
NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
|
|
|
G |
Ar |
androgen receptor |
multiple interactions increases expression |
ISO |
formestane metabolite inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA] formestane analog results in increased expression of AR mRNA; formestane metabolite results in increased expression of AR mRNA; formestane results in increased expression of AR mRNA |
CTD |
PMID:29702199 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
formestane promotes the reaction [Androstenedione results in increased expression of CYP11A1 mRNA]; formestane promotes the reaction [Testosterone results in increased expression of CYP11A1 mRNA] |
CTD |
PMID:21273442 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions decreases activity |
ISO EXP |
formestane inhibits the reaction [Atrazine results in increased activity of CYP19A1 protein]; formestane inhibits the reaction [CYP19A1 protein affects the chemical synthesis of 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine]; formestane inhibits the reaction [CYP19A1 protein affects the metabolism of Methadone]; formestane inhibits the reaction [propazine results in increased activity of CYP19A1 protein]; formestane inhibits the reaction [Simazine results in increased activity of CYP19A1 protein] formestane results in decreased activity of CYP19A1 protein formestane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; formestane inhibits the reaction [FSHB protein results in increased activity of CYP19A1 protein]; formestane promotes the reaction [Androstenedione results in increased expression of CYP19A1 mRNA]; formestane promotes the reaction [Testosterone results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:10746939 PMID:10806373 PMID:15242824 PMID:15319488 PMID:16177243 PMID:16996190 PMID:17895526 PMID:21126571 PMID:21273442 PMID:21341743 PMID:22120136 More...
|
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression |
ISO |
formestane metabolite results in increased expression of ESR1 mRNA |
CTD |
PMID:29702199 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
formestane inhibits the reaction [FSHB protein results in increased activity of CYP19A1 protein] |
CTD |
PMID:22120136 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
decreases activity |
ISO |
formestane results in decreased activity of HSD17B1 protein |
CTD |
PMID:15876411 |
|
NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,009,728...86,011,927
|
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of and results in increased cleavage of CASP1 protein] hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein] |
CTD |
PMID:37001609 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
EXP |
hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Particulate Matter results in increased expression of CD40 protein]]; hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Vehicle Emissions results in increased expression of CD40 protein]]; hydroxysafflor yellow A inhibits the reaction [Vehicle Emissions results in increased expression of CD40 protein] |
CTD |
PMID:24192212 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd40lg |
CD40 ligand |
multiple interactions |
EXP |
hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Particulate Matter results in increased expression of CD40LG protein]]; hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Vehicle Emissions results in increased expression of CD40LG protein]]; hydroxysafflor yellow A inhibits the reaction [Particulate Matter results in increased expression of CD40LG protein]; hydroxysafflor yellow A inhibits the reaction [Vehicle Emissions results in increased expression of CD40LG protein] |
CTD |
PMID:24192212 |
|
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions |
ISO |
hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein] |
CTD |
PMID:37001609 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
ISO |
HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein] hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased cleavage of GSDMD protein] |
CTD |
PMID:37001609 |
|
NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055
|
|
G |
Hk1 |
hexokinase 1 |
multiple interactions |
ISO |
hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased expression of HK1 protein] HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of HK1 protein] |
CTD |
PMID:37001609 |
|
NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases expression |
EXP ISO |
hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Particulate Matter results in increased expression of ICAM1 protein]]; hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Vehicle Emissions results in increased expression of ICAM1 protein]]; hydroxysafflor yellow A inhibits the reaction [Particulate Matter results in increased expression of ICAM1 protein]; hydroxysafflor yellow A inhibits the reaction [Vehicle Emissions results in increased expression of ICAM1 protein] hydroxysafflor yellow A results in decreased expression of ICAM1 protein hydroxysafflor yellow A inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA] |
CTD |
PMID:22007554 PMID:24192212 PMID:32705535 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased secretion of IL18 protein] |
CTD |
PMID:37001609 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of IL1B protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein] hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased cleavage of IL1B protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein] |
CTD |
PMID:37001609 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Particulate Matter results in increased expression of IL6 protein]]; hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Vehicle Emissions results in increased expression of IL6 protein]]; hydroxysafflor yellow A inhibits the reaction [Particulate Matter results in increased expression of IL6 protein]; hydroxysafflor yellow A inhibits the reaction [Vehicle Emissions results in increased expression of IL6 protein] hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased secretion of IL6 protein] hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL6 protein]; hydroxysafflor yellow A inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:22007554 PMID:24192212 PMID:37001609 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
EXP |
hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Particulate Matter results in increased expression of ITGB3 protein]]; hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Vehicle Emissions results in increased expression of ITGB3 protein]]; hydroxysafflor yellow A inhibits the reaction [Particulate Matter results in increased expression of ITGB3 protein]; hydroxysafflor yellow A inhibits the reaction [Vehicle Emissions results in increased expression of ITGB3 protein] |
CTD |
PMID:24192212 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
EXP ISO |
hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Particulate Matter results in increased expression of MMP9 protein]]; hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Vehicle Emissions results in increased expression of MMP9 protein]]; hydroxysafflor yellow A inhibits the reaction [Particulate Matter results in increased expression of MMP9 protein]; hydroxysafflor yellow A inhibits the reaction [Vehicle Emissions results in increased expression of MMP9 protein] hydroxysafflor yellow A results in decreased expression of MMP9 protein |
CTD |
PMID:24192212 PMID:32705535 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein] |
CTD |
PMID:37001609 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
hydroxysafflor yellow A results in decreased phosphorylation of and results in decreased expression of NFKBIA protein modified form |
CTD |
PMID:32705535 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 protein] |
CTD |
PMID:37001609 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN protein] |
CTD |
PMID:37001609 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Particulate Matter results in decreased expression of PPARG protein]]; hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Vehicle Emissions results in decreased expression of PPARG protein]]; hydroxysafflor yellow A inhibits the reaction [Particulate Matter results in decreased expression of PPARG protein]; hydroxysafflor yellow A inhibits the reaction [Vehicle Emissions results in decreased expression of PPARG protein] |
CTD |
PMID:24192212 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
EXP |
hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Particulate Matter results in decreased activity of PRKACA protein]]; hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Vehicle Emissions results in decreased activity of PRKACA protein]]; hydroxysafflor yellow A inhibits the reaction [Particulate Matter results in decreased activity of PRKACA protein]; hydroxysafflor yellow A inhibits the reaction [Vehicle Emissions results in decreased activity of PRKACA protein] |
CTD |
PMID:24192212 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
hydroxysafflor yellow A results in decreased phosphorylation of and results in decreased expression of RELA protein modified form |
CTD |
PMID:32705535 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of TNF protein]; hydroxysafflor yellow A inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased secretion of TNF protein] hydroxysafflor yellow A results in decreased expression of TNF protein hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Particulate Matter results in increased expression of TNF protein]]; hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Vehicle Emissions results in increased expression of TNF protein]]; hydroxysafflor yellow A inhibits the reaction [Particulate Matter results in increased expression of TNF protein]; hydroxysafflor yellow A inhibits the reaction [Vehicle Emissions results in increased expression of TNF protein] |
CTD |
PMID:22007554 PMID:24192212 PMID:32705535 PMID:37001609 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions decreases expression |
ISO EXP |
hydroxysafflor yellow A inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 mRNA] hydroxysafflor yellow A results in decreased expression of VCAM1 protein hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Particulate Matter results in increased expression of VCAM1 protein]]; hydroxysafflor yellow A inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [Vehicle Emissions results in increased expression of VCAM1 protein]]; hydroxysafflor yellow A inhibits the reaction [Particulate Matter results in increased expression of VCAM1 protein]; hydroxysafflor yellow A inhibits the reaction [Vehicle Emissions results in increased expression of VCAM1 protein] |
CTD |
PMID:22007554 PMID:24192212 PMID:32705535 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
ilimaquinone results in decreased expression of BCL2 protein |
CTD |
PMID:24930757 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
ilimaquinone results in decreased expression of BCL2L1 protein |
CTD |
PMID:24930757 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO |
[ilimaquinone results in increased susceptibility to TNFSF10 protein] which results in increased cleavage of CASP3 protein; ilimaquinone promotes the reaction [TNFSF10 protein results in increased cleavage of CASP3 protein] ilimaquinone results in increased cleavage of CASP3 protein |
CTD |
PMID:24930757 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases cleavage |
ISO |
ilimaquinone results in increased cleavage of CASP8 protein |
CTD |
PMID:24930757 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [ilimaquinone results in increased expression of DDIT3 mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [ilimaquinone results in increased expression of DDIT3 mRNA]; Acetylcysteine inhibits the reaction [ilimaquinone results in increased expression of DDIT3 mRNA] |
CTD |
PMID:24930757 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
ilimaquinone results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:24930757 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
ilimaquinone results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:24930757 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
[ilimaquinone results in increased susceptibility to TNFSF10 protein] which results in increased cleavage of PARP1 protein; ilimaquinone promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein] ilimaquinone results in increased cleavage of PARP1 protein |
CTD |
PMID:24930757 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pld2 |
phospholipase D2 |
multiple interactions increases activity |
ISO |
1-Butanol inhibits the reaction [ilimaquinone results in increased activity of PLD2 protein] |
CTD |
PMID:17897952 |
|
NCBI chr10:55,256,326...55,274,192
Ensembl chr10:55,256,359...55,272,808
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [ilimaquinone results in increased expression of TNFRSF10A mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [ilimaquinone results in increased expression of TNFRSF10A protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [ilimaquinone results in increased expression of TNFRSF10A mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [ilimaquinone results in increased expression of TNFRSF10A protein]; Acetylcysteine inhibits the reaction [ilimaquinone results in increased expression of TNFRSF10A mRNA] ilimaquinone results in increased expression of TNFRSF10A mRNA; ilimaquinone results in increased expression of TNFRSF10A protein |
CTD |
PMID:24930757 |
|
NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
[ilimaquinone results in increased susceptibility to TNFSF10 protein] which results in increased cleavage of CASP3 protein; [ilimaquinone results in increased susceptibility to TNFSF10 protein] which results in increased cleavage of PARP1 protein; ilimaquinone promotes the reaction [TNFSF10 protein results in increased cleavage of CASP3 protein]; ilimaquinone promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein] |
CTD |
PMID:24930757 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
|
G |
Acan |
aggrecan |
multiple interactions |
ISO |
Ionomycin affects the reaction [CALR protein affects the expression of ACAN mRNA] |
CTD |
PMID:32220932 |
|
NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Actb |
actin, beta |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ACTB mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ACTB mRNA |
CTD |
PMID:15477007 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Actn1 |
actinin, alpha 1 |
multiple interactions |
EXP |
Ionomycin promotes the reaction [CAMK2A protein binds to ACTN1 protein] |
CTD |
PMID:19217379 |
|
NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
|
|
G |
Adm |
adrenomedullin |
decreases expression multiple interactions |
EXP ISO |
Ionomycin results in decreased expression of ADM mRNA Ionomycin results in decreased expression of ADM mRNA; Ionomycin results in decreased expression of ADM protein [Ionomycin co-treated with Lipopolysaccharides] results in decreased expression of ADM protein |
CTD |
PMID:11470465 PMID:20682585 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of AHR mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and affects the localization of AHR protein |
CTD |
PMID:9415701 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein; [Ionomycin co-treated with EGF protein] results in increased phosphorylation of AKT1 protein; CAMKK2 protein affects the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; PDK1 protein affects the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; PX-866 inhibits the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; STO 609 inhibits the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; W 7 inhibits the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:22317921 PMID:28634229 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Arpc2 |
actin related protein 2/3 complex, subunit 2 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ARPC2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ARPC2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 9:75,820,782...75,851,471
Ensembl chr 9:75,820,770...75,851,471
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions increases expression |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ATF4 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ATF4 mRNA Ionomycin results in increased expression of ATF4 protein |
CTD |
PMID:15477007 PMID:32578922 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
multiple interactions |
ISO |
[Thapsigargin co-treated with Ionomycin] promotes the reaction [STIM1 protein binds to ATP2A3 protein] |
CTD |
PMID:18439569 |
|
NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748
|
|
G |
Bach2 |
BTB domain and CNC homolog 2 |
increases expression |
ISO |
Ionomycin results in increased expression of BACH2 mRNA |
CTD |
PMID:24247028 |
|
NCBI chr 5:46,632,338...46,982,676
Ensembl chr 5:46,638,317...46,977,877
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
Ionomycin affects the reaction [CALR protein affects the expression of BGLAP mRNA] |
CTD |
PMID:32220932 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
C5ar1 |
complement C5a receptor 1 |
increases expression |
ISO |
Ionomycin results in increased expression of C5AR1 protein |
CTD |
PMID:18559098 |
|
NCBI chr 1:76,948,622...76,959,826
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions increases expression |
EXP ISO |
Ionomycin inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA] Ionomycin results in increased expression of CALCA mRNA [Ionomycin co-treated with Lipopolysaccharides] results in increased expression of CALCA protein; Ionomycin promotes the reaction [Lipopolysaccharides results in increased expression of CALCA mRNA]; Verapamil inhibits the reaction [[Ionomycin co-treated with Lipopolysaccharides] results in increased expression of CALCA protein] Ionomycin results in increased expression of CALCA protein |
CTD |
PMID:2470235 PMID:12574409 PMID:20682585 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Calr |
calreticulin |
decreases response to substance multiple interactions |
ISO |
CALR protein results in decreased susceptibility to Ionomycin Ionomycin affects the reaction [CALR protein affects the expression of ACAN mRNA]; Ionomycin affects the reaction [CALR protein affects the expression of BGLAP mRNA]; Ionomycin affects the reaction [CALR protein affects the expression of RUNX2 mRNA]; Ionomycin affects the reaction [CALR protein affects the expression of SOX9 mRNA]; Ionomycin affects the reaction [CALR protein affects the expression of SP7 mRNA] |
CTD |
PMID:7961812 PMID:32220932 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions |
EXP |
[Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; Ionomycin promotes the reaction [CAMK2A protein binds to ACTN1 protein]; Ionomycin promotes the reaction [CAMK2A protein binds to CDK5R1 protein]; Ionomycin promotes the reaction [CAMK2A protein binds to DRD3 protein]; Ionomycin promotes the reaction [CAMK2A protein binds to GRIN2B protein]; Ionomycin promotes the reaction [CAMK2A protein modified form binds to DRD3 protein]; KN 93 inhibits the reaction [Ionomycin promotes the reaction [CAMK2A protein binds to DRD3 protein]]; KN 93 inhibits the reaction [Ionomycin promotes the reaction [CAMK2A protein modified form binds to DRD3 protein]] |
CTD |
PMID:19217379 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
multiple interactions |
ISO |
[Ionomycin co-treated with Calcium co-treated with CAMK2D protein] results in increased activity of TRPM4 protein |
CTD |
PMID:33392831 |
|
NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2 |
multiple interactions |
ISO |
CAMKK2 protein affects the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:28634229 |
|
NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CASP3 protein; Calcium deficiency inhibits the reaction [Ionomycin results in increased activity of CASP3 protein] |
CTD |
PMID:12165276 PMID:29803841 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CASP8 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA] |
CTD |
PMID:12165276 PMID:15477007 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL11 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL11 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL11 protein] |
CTD |
PMID:17572062 PMID:17685462 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL2 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL2 protein] |
CTD |
PMID:17572062 PMID:17685462 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL3 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 protein; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA] |
CTD |
PMID:15477007 PMID:17572062 PMID:17685462 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL4 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL4 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL4 protein] |
CTD |
PMID:17572062 PMID:17685462 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL5 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL5 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL5 protein] |
CTD |
PMID:17572062 PMID:17685462 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CCNG1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CCNG1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 2:82,591,750...82,602,903
Ensembl chr 2:82,590,630...82,602,930
|
|
G |
Cd200 |
Cd200 molecule |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648
|
|
G |
Cd40lg |
CD40 ligand |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD40LG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD40LG protein |
CTD |
PMID:22851303 |
|
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD44 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD44 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
increases expression |
ISO |
Ionomycin results in increased expression of CD55 mRNA |
CTD |
PMID:24247028 |
|
NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831
|
|
G |
Cd69 |
Cd69 molecule |
increases expression multiple interactions |
ISO |
Ionomycin results in increased expression of CD69 mRNA [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD69 protein 2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD69 protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD69 protein |
CTD |
PMID:23134680 PMID:24247028 PMID:26343699 PMID:30171972 |
|
NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
[diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein |
CTD |
PMID:31958493 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd86 |
CD86 molecule |
decreases expression multiple interactions |
ISO |
Ionomycin results in decreased expression of CD86 protein [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; PRKCB protein affects the reaction [[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein] |
CTD |
PMID:23376802 PMID:31958493 PMID:37326882 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdh17 |
cadherin 17 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 5:25,262,820...25,314,884
Ensembl chr 5:25,262,758...25,314,884
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
multiple interactions |
EXP |
Ionomycin promotes the reaction [CAMK2A protein binds to CDK5R1 protein] |
CTD |
PMID:19217379 |
|
NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
|
|
G |
Cfl1 |
cofilin 1 |
multiple interactions |
ISO |
Egtazic Acid inhibits the reaction [Ionomycin results in decreased phosphorylation of and results in increased activity of CFL1 protein]; Ionomycin results in decreased phosphorylation of and results in increased activity of CFL1 protein |
CTD |
PMID:17303079 |
|
NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Cftr |
CF transmembrane conductance regulator |
increases activity |
EXP |
Ionomycin results in increased activity of CFTR protein |
CTD |
PMID:15389550 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CHUK protein; Auranofin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CHUK protein] |
CTD |
PMID:10820281 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cln3 |
CLN3 lysosomal/endosomal transmembrane protein, battenin |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CLN3 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CLN3 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:181,156,071...181,169,458
Ensembl chr 1:181,156,073...181,167,434
|
|
G |
Cln8 |
CLN8, transmembrane ER and ERGIC protein |
multiple interactions |
ISO |
CLN8 protein affects the reaction [[Ionomycin co-treated with Calcium] results in increased transport of D-Aspartic Acid] |
CTD |
PMID:22302580 |
|
NCBI chr16:74,749,662...74,759,553
Ensembl chr16:74,749,662...74,759,774
|
|
G |
Col6a1 |
collagen type VI alpha 1 chain |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of COL6A1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of COL6A1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of COMT mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of COMT mRNA |
CTD |
PMID:15477007 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Crem |
cAMP responsive element modulator |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in decreased expression of MIR146A mRNA; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of MIR27A mRNA; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CSF2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CSF2 protein; PRKCB protein affects the reaction [[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CSF2 protein] |
CTD |
PMID:17572062 PMID:17685462 PMID:37326882 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csnk2a1 |
casein kinase 2 alpha 1 |
multiple interactions |
ISO |
Ionomycin promotes the reaction [EGF protein promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]] |
CTD |
PMID:22317921 |
|
NCBI chr 3:140,709,984...140,756,757
Ensembl chr 3:140,709,991...140,756,696
|
|
G |
Ctbp1 |
C-terminal binding protein 1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CTBP1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CTBP1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr14:77,455,580...77,482,821
Ensembl chr14:77,455,696...77,482,821
|
|
G |
Cul5 |
cullin 5 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 8:54,012,963...54,066,751
Ensembl chr 8:54,016,006...54,066,666
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CYP1A1 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CYP1A1 protein |
CTD |
PMID:9415701 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Ionomycin results in increased expression of DDIT3 protein |
CTD |
PMID:32578922 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DNAJC3 mRNA; deoxynivalenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DNAJC3 mRNA] |
CTD |
PMID:10652249 |
|
NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein; Okadaic Acid promotes the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein] |
CTD |
PMID:23775084 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which binds to DPYD promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which results in increased expression of DPYD mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DPYD mRNA |
CTD |
PMID:15705907 |
|
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
|
|
G |
Drd3 |
dopamine receptor D3 |
multiple interactions increases phosphorylation |
EXP |
[Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; Ionomycin inhibits the reaction [[3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol results in increased activity of DRD3 protein] which results in increased phosphorylation of MAPK1 protein]; Ionomycin promotes the reaction [CAMK2A protein binds to DRD3 protein]; Ionomycin promotes the reaction [CAMK2A protein modified form binds to DRD3 protein]; KN 93 inhibits the reaction [Ionomycin promotes the reaction [CAMK2A protein binds to DRD3 protein]]; KN 93 inhibits the reaction [Ionomycin promotes the reaction [CAMK2A protein modified form binds to DRD3 protein]]; KN 93 inhibits the reaction [Ionomycin results in increased phosphorylation of DRD3 protein] |
CTD |
PMID:19217379 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[Ionomycin co-treated with EGF protein] results in increased phosphorylation of AKT1 protein; [Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK1 protein; [Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK3 protein; Ionomycin promotes the reaction [EGF protein promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]] |
CTD |
PMID:22317921 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[Ionomycin results in increased abundance of Calcium] which results in increased expression of EGR1 protein |
CTD |
PMID:12517959 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Evi2a |
ecotropic viral integration site 2A |
increases expression |
ISO |
Ionomycin results in increased expression of EVI2A mRNA |
CTD |
PMID:24247028 |
|
NCBI chr10:64,485,760...64,489,660
Ensembl chr10:64,485,200...64,489,843
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Estradiol] results in decreased expression of FASLG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Estradiol] results in decreased expression of FASLG protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Testosterone] results in increased expression of FASLG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Testosterone] results in increased expression of FASLG protein; Tamoxifen inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Estradiol] results in decreased expression of FASLG mRNA] |
CTD |
PMID:20529085 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO EXP |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which binds to DPYD promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which results in increased expression of DPYD mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein]]; Capsaicin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein] Ionomycin results in increased expression of FOS mRNA 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Ionomycin results in increased expression of FOS mRNA] |
CTD |
PMID:9580328 PMID:9650640 PMID:15477007 PMID:15705907 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOSL2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOSL2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034
|
|
G |
Fyb1 |
FYN binding protein 1 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 2:55,621,585...55,781,206
Ensembl chr 2:55,632,698...55,779,629
|
|
G |
Gata3 |
GATA binding protein 3 |
multiple interactions |
ISO |
[PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GATA3 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GATA3 mRNA |
CTD |
PMID:22398747 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Gfra2 |
GDNF family receptor alpha 2 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr15:45,941,841...46,033,715
Ensembl chr15:45,941,828...46,033,714
|
|
G |
Gh1 |
growth hormone 1 |
increases secretion |
ISO |
Ionomycin results in increased secretion of GH1 protein |
CTD |
PMID:12471042 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
EXP |
Ionomycin promotes the reaction [CAMK2A protein binds to GRIN2B protein] |
CTD |
PMID:19217379 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Gzmb |
granzyme B |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GZMB protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GZMB protein |
CTD |
PMID:30171972 |
|
NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HADHA mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HADHA mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
|
|
G |
Hars1 |
histidyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HARS1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HARS1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr18:28,381,649...28,398,699
Ensembl chr18:28,381,655...28,398,740
|
|
G |
Hck |
HCK proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HCK mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HCK mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693
|
|
G |
Hexb |
hexosaminidase subunit beta |
increases secretion multiple interactions |
ISO EXP |
Ionomycin results in increased secretion of HEXB protein Cyclosporine inhibits the reaction [Ionomycin results in increased secretion of HEXB protein]; KN 93 inhibits the reaction [Ionomycin results in increased secretion of HEXB protein]; ML 7 inhibits the reaction [Ionomycin results in increased secretion of HEXB protein]; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide inhibits the reaction [Ionomycin results in increased secretion of HEXB protein] |
CTD |
PMID:14499669 PMID:19758318 |
|
NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases activity |
ISO |
Curcumin analog inhibits the reaction [Ionomycin promotes the reaction [Oxygen deficiency results in increased activity of HIF1A protein]]; Curcumin analog inhibits the reaction [Ionomycin results in increased activity of HIF1A protein]; Ionomycin promotes the reaction [Oxygen deficiency results in increased activity of HIF1A protein] |
CTD |
PMID:20554536 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hk2 |
hexokinase 2 |
increases expression |
EXP |
Ionomycin results in increased expression of HK2 mRNA |
CTD |
PMID:17516843 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HMGB1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HMGB1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hrh2 |
histamine receptor H 2 |
multiple interactions |
ISO |
HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]] |
CTD |
PMID:19277450 |
|
NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA5 mRNA; deoxynivalenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA5 mRNA]; deoxynivalenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA5 protein] |
CTD |
PMID:10652249 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA8 mRNA]]; pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA8 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO EXP |
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; [Benzocaine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG protein; [Mercuric Chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [tetrachloroplatinate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IFNG protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein; [Thalidomide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; Estradiol affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IFNG protein]; Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; Resveratrol affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IFNG protein]; tamibarotene inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG protein] 2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [2,4-diaminotoluene co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [2-anthramine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [4-nitroaniline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Acetaminophen co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Aluminum Chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Amphotericin B co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Azathioprine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Chloroquine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Chlorpromazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Cisplatin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [citral co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [cobaltous chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Colchicine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Cyclophosphamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dactinomycin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dapsone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [dibenzo(a,i)pyrene co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dibutyl Phthalate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [Digoxin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dimethyl Sulfoxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [FR 167653 co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Histamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Hydrocortisone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Hydrogen Peroxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IFNG promoter; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IFNG protein; [lead acetate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Lithium Carbonate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Mercuric Chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Methotrexate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Minocycline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Mycophenolic Acid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [nickel sulfate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Nitrofurazone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Ribavirin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Sulfasalazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Tacrolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IFNG protein; [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [Trichloroethylene co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [triethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Vehicle Emissions co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG protein]; Aspirin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IFNG protein]; Cyclosporine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; nickel chloride inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IFNG promoter]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IFNG protein]; Zinc deficiency affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; benzamide inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA]; phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA] |
CTD |
PMID:12411406 PMID:12812920 PMID:15358692 PMID:15379866 PMID:15588918 PMID:16154495 PMID:16716911 PMID:17475810 PMID:17572062 PMID:17685462 PMID:19277450 PMID:21569788 PMID:22077062 PMID:22398747 PMID:25073960 PMID:26343699 PMID:29594315 PMID:30171972 More...
|
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ifngr2 |
interferon gamma receptor 2 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNGR2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNGR2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr11:30,779,733...30,798,005
Ensembl chr11:30,779,733...30,798,005
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO EXP |
4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein; Acetaminophen affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; bisphenol A affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; catechol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; hydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; hydroxyhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; quinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein] [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA [Benzocaine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA]; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IL10 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein; Genistein affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IL10 protein] |
CTD |
PMID:12884291 PMID:15588918 PMID:16716911 PMID:17572062 PMID:17685462 PMID:19277450 PMID:22398747 PMID:29777833 More...
|
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL13 mRNA; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL13 mRNA] |
CTD |
PMID:22398747 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA; biochanin A promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; daidzein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; enilconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; formononetin promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; Genistein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; hexaconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; T0901317 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; tetraconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; triflumizol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA] [Trinitrobenzenesulfonic Acid results in increased susceptibility to [Ionomycin co-treated with Tetradecanoylphorbol Acetate]] which results in increased expression of IL17A protein |
CTD |
PMID:22289359 PMID:25583575 PMID:27783946 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[Ionomycin co-treated with IL1A protein] results in decreased secretion of IL4 protein; [Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein; [Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein; [Ionomycin co-treated with IL1A protein] results in increased secretion of TNF protein; IL1A protein promotes the reaction [Ionomycin results in increased expression of IL9 mRNA]; IL1RN protein inhibits the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL3 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein] |
CTD |
PMID:10820229 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL1B protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL1B protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL1B protein] |
CTD |
PMID:17572062 PMID:17685462 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions |
ISO |
IL1RN protein inhibits the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein] |
CTD |
PMID:10820229 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il2 |
interleukin 2 |
multiple interactions increases expression |
ISO EXP |
[Benzocaine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [bis(tri-n-butyltin)oxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein; [Sodium Dodecyl Sulfate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [tetrachloroplatinate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with IL2 protein] results in increased expression of IL2RA protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein; [Thalidomide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; anethole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; anethole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; Cannabinol inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]; Cannabinol inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with IL2 protein] results in increased expression of IL2RA protein]; Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; Dronabinol inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]; Dronabinol inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; isoeugenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; isoeugenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein] 1-Butanol inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]]; 4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; [2-anthramine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [4-nitroaniline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Acetaminophen co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Aluminum Chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Amphotericin B co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Chloroquine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Chlorpromazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Cisplatin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [citral co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [cobaltous chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Colchicine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dactinomycin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dapsone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dexamethasone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [dibenzo(a,i)pyrene co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dibutyl Phthalate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Dichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [diethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Digoxin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dimethyl Sulfoxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Formaldehyde co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [FR 167653 co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Histamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Hydrocortisone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Hydrogen Peroxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 promoter; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein; [Isoniazid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [isophorone diisocyanate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [lead acetate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Lithium Carbonate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Methotrexate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Minocycline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Mitomycin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Mycophenolic Acid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [nickel sulfate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Nitrofurazone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Pyrimethamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Ribavirin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [sodium bromate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Sulfasalazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Tacrolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein; [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [Trichloroethylene co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Trichloroethylene co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [triethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Vehicle Emissions co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Warfarin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein]; Aspirin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]]; bisphenol A affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Diclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Go 6976 inhibits the reaction [pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Lenalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; NECAME_02783 protein modified form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; nickel chloride inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 promoter]; norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Peptides inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; Pyrazoles analog inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; Pyrazoles analog inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; Quercetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; rottlerin inhibits the reaction [pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; SB 203580 inhibits the reaction [norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; tert-Butyl Alcohol inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; U 0126 inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; Zinc deficiency affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; Zinc Sulfate inhibits the reaction [Ionomycin results in increased expression of IL2 mRNA] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; benzamide inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]; phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA] |
CTD |
PMID:8658534 PMID:8662742 PMID:9439728 PMID:11592964 PMID:12165276 PMID:12411406 PMID:12812920 PMID:15379866 PMID:15477007 PMID:15588918 PMID:16055081 PMID:16154495 PMID:16241859 PMID:16531003 PMID:17572062 PMID:17615583 PMID:17630204 PMID:17685462 PMID:18423386 PMID:19277450 PMID:19880376 PMID:21075198 PMID:21569788 PMID:22398747 PMID:23134680 PMID:25073960 PMID:26343699 PMID:29594315 PMID:29777833 PMID:34051231 More...
|
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il21 |
interleukin 21 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL21 protein; tamibarotene inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL21 protein] |
CTD |
PMID:22077062 |
|
NCBI chr 2:120,117,105...120,127,012
Ensembl chr 2:120,119,444...120,126,996
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
multiple interactions increases secretion |
ISO EXP |
[Dichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2RA protein; [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein; [Trichloroethylene co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein; Cyclosporine inhibits the reaction [Ionomycin results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [Ionomycin results in increased secretion of IL2RA protein] 2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with IL2 protein] results in increased expression of IL2RA protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein; Acetylcysteine inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]]; bathocuproine sulfonate inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with IL2 protein] results in increased expression of IL2RA protein]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA mRNA]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA mRNA]; tetrathiomolybdate inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2RA protein |
CTD |
PMID:8586487 PMID:9766631 PMID:22398747 PMID:23134680 PMID:26343699 PMID:30171972 More...
|
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Il2rb |
interleukin 2 receptor subunit beta |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 7:110,033,341...110,048,054
Ensembl chr 7:110,033,341...110,048,054
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
ISO |
IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL3 protein] |
CTD |
PMID:10820229 |
|
NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO EXP |
4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL4 protein]; [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in decreased expression of MIR146A mRNA; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of MIR27A mRNA; [Ionomycin co-treated with IL1A protein] results in decreased secretion of IL4 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL4 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL4 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL4 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL3 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein]; PRKCB protein affects the reaction [[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL4 protein] [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA; Cyclosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]]; IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]; Staurosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]] [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein; [Toluene 2,4-Diisocyanate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL4 protein; bisphenol A promotes the reaction [[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]; Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]; Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; nonylphenol promotes the reaction [[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA] |
CTD |
PMID:8658534 PMID:9766631 PMID:10820229 PMID:12709020 PMID:12884291 PMID:15588918 PMID:17572062 PMID:17685462 PMID:19277450 PMID:22398747 PMID:25073960 PMID:29777833 PMID:31958493 PMID:37326882 More...
|
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO EXP |
2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL5 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 protein; Cyclosporine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL5 protein] deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 protein] |
CTD |
PMID:8658534 PMID:12884291 PMID:17475810 PMID:17572062 PMID:17685462 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO EXP |
4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein]; [Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein; [Ionomycin co-treated with Lipopolysaccharides] results in increased expression of IL6 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL6 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL6 protein; Acetaminophen affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein]; bisphenol A affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein]; Diclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein]; Ionomycin promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein] Ionomycin results in increased expression of IL6 mRNA |
CTD |
PMID:10820229 PMID:12884291 PMID:17572062 PMID:17685462 PMID:18434080 PMID:20682585 PMID:22398747 PMID:29777833 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il9 |
interleukin 9 |
increases expression multiple interactions |
ISO |
Ionomycin results in increased expression of IL9 mRNA [Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein; IL1A protein promotes the reaction [Ionomycin results in increased expression of IL9 mRNA]; IL1RN protein inhibits the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein] |
CTD |
PMID:10820229 |
|
NCBI chr17:8,111,772...8,114,895
Ensembl chr17:8,111,772...8,114,895
|
|
G |
Irf4 |
interferon regulatory factor 4 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IRF4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IRF4 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of JUN protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which binds to DPYD promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which results in increased expression of DPYD mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of JUN protein]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein]]; Capsaicin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein]; Methohexital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]; Pentobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]; pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein]; Secobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]; Thiamylal inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]; Thiopental inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA] |
CTD |
PMID:9580328 PMID:15263067 PMID:15477007 PMID:15705907 PMID:25073960 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnn3 |
potassium calcium-activated channel subfamily N member 3 |
multiple interactions increases activity |
EXP |
[Ionomycin results in increased activity of KCNN3 protein] which results in increased import of Thallium; Apamin inhibits the reaction [[Ionomycin results in increased activity of KCNN3 protein] which results in increased import of Thallium] |
CTD |
PMID:15634793 |
|
NCBI chr 2:174,929,846...175,088,910
Ensembl chr 2:174,936,629...175,081,145
|
|
G |
Kcnn4 |
potassium calcium-activated channel subfamily N member 4 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetraethylammonium] results in increased activity of KCNN4 protein; Clotrimazole inhibits the reaction [[Ionomycin co-treated with Tetraethylammonium] results in increased activity of KCNN4 protein] |
CTD |
PMID:14985237 |
|
NCBI chr 1:79,956,380...79,974,354
Ensembl chr 1:79,959,322...79,974,340
|
|
G |
Klf4 |
KLF transcription factor 4 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of KLF4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of KLF4 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Klf6 |
KLF transcription factor 6 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of KLF6 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of KLF6 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Kpnb1 |
karyopherin subunit beta 1 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]] |
CTD |
PMID:17615583 |
|
NCBI chr10:82,145,662...82,174,437
Ensembl chr10:82,145,420...82,174,605
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
multiple interactions |
ISO |
Methohexital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]; Pentobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]; Secobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]; Thiamylal inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein] |
CTD |
PMID:15263067 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
increases expression |
ISO |
Ionomycin results in increased expression of LAMP1 protein |
CTD |
PMID:23376802 |
|
NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883
|
|
G |
Lcp1 |
lymphocyte cytosolic protein 1 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of LCP1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of LCP1 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr15:50,443,300...50,544,682
Ensembl chr15:50,488,149...50,544,680
|
|
G |
Ltbp4 |
latent transforming growth factor beta binding protein 4 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:82,600,136...82,634,346
Ensembl chr 1:82,600,136...82,632,178
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
Ionomycin inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA] |
CTD |
PMID:12574409 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MAP2K2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MAP2K2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
1-Butanol inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; [Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK1 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein]]; Okadaic Acid promotes the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein] [Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; Ionomycin inhibits the reaction [[3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol results in increased activity of DRD3 protein] which results in increased phosphorylation of MAPK1 protein]; Ionomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:15477007 PMID:16877402 PMID:18423386 PMID:19217379 PMID:22317921 PMID:23134680 PMID:23775084 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
[Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK3 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein]]; Okadaic Acid promotes the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]; pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein] Ionomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15477007 PMID:16877402 PMID:18423386 PMID:22317921 PMID:23134680 PMID:23775084 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK8 protein; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:25073960 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases phosphorylation multiple interactions |
ISO EXP |
Ionomycin results in decreased phosphorylation of MAPT protein Okadaic Acid inhibits the reaction [Ionomycin results in decreased phosphorylation of MAPT protein] |
CTD |
PMID:9200503 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mir146a |
microRNA 146a |
multiple interactions |
ISO |
[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in decreased expression of MIR146A mRNA |
CTD |
PMID:37326882 |
|
NCBI chr10:27,848,516...27,848,610
Ensembl chr10:27,848,516...27,848,610
|
|
G |
Mir27a |
microRNA 27a |
multiple interactions |
ISO |
[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of MIR27A mRNA |
CTD |
PMID:37326882 |
|
NCBI chr19:23,954,831...23,954,917
Ensembl chr19:23,954,831...23,954,917
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myl9 |
myosin light chain 9 |
increases phosphorylation multiple interactions |
EXP |
Ionomycin results in increased phosphorylation of MYL9 protein Trifluoperazine inhibits the reaction [Ionomycin results in increased phosphorylation of MYL9 protein] |
CTD |
PMID:19233221 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Naa80 |
N(alpha)-acetyltransferase 80, NatH catalytic subunit |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NAA80 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NAA80 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 8:108,254,314...108,257,564
Ensembl chr 8:108,253,302...108,257,563
|
|
G |
Ncs1 |
neuronal calcium sensor 1 |
increases response to substance |
EXP |
NCS1 protein results in increased susceptibility to Ionomycin |
CTD |
PMID:12471042 |
|
NCBI chr 3:14,523,220...14,568,829
Ensembl chr 3:14,523,220...14,568,829
|
|
G |
Nell1 |
neural EGFL like 1 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NELL1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NELL1 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 1:99,709,305...100,573,872
Ensembl chr 1:99,709,793...100,573,860
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions decreases phosphorylation |
ISO |
Hydrogen Peroxide inhibits the reaction [Ionomycin results in decreased phosphorylation of NFATC1 protein] |
CTD |
PMID:12203019 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfatc2 |
nuclear factor of activated T-cells 2 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein; Acetic Acid inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of and results in decreased phosphorylation of NFATC2 protein; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein] |
CTD |
PMID:17615583 |
|
NCBI chr 3:157,195,970...157,328,640
Ensembl chr 3:157,198,872...157,328,325
|
|
G |
Nfatc3 |
nuclear factor of activated T-cells 3 |
multiple interactions affects localization |
ISO EXP |
[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]; bisphenol A promotes the reaction [[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA]; nonylphenol promotes the reaction [[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA] Ionomycin affects the localization of NFATC3 protein |
CTD |
PMID:12709020 PMID:15799720 |
|
NCBI chr19:33,960,643...34,035,150
Ensembl chr19:33,960,852...34,035,150
|
|
G |
Nfatc4 |
nuclear factor of activated T-cells 4 |
increases localization |
EXP |
Ionomycin results in increased localization of NFATC4 protein |
CTD |
PMID:16849427 |
|
NCBI chr15:29,286,998...29,314,610
Ensembl chr15:29,305,535...29,314,610
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases response to substance multiple interactions decreases response to substance |
ISO |
NFE2L2 gene mutant form results in increased susceptibility to Ionomycin [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of NFE2L2 protein NFE2L2 protein results in decreased susceptibility to Ionomycin |
CTD |
PMID:12842875 PMID:24632381 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased degradation of NFKBIA protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased degradation of NFKBIA protein; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased degradation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased degradation of NFKBIA protein] |
CTD |
PMID:15477007 PMID:25073960 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nkg7 |
natural killer cell granule protein 7 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NKG7 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NKG7 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:93,844,748...93,845,975
Ensembl chr 1:93,844,902...93,845,983
|
|
G |
Nmi |
N-myc (and STAT) interactor |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NMI mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NMI mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 3:36,415,607...36,439,716
Ensembl chr 3:36,415,607...36,439,498
|
|
G |
Notch3 |
notch receptor 3 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NOTCH3 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NOTCH3 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NR4A3 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NR4A3 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions |
ISO |
PDK1 protein affects the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:28634229 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Plcb1 |
phospholipase C beta 1 |
multiple interactions |
EXP |
PLCB1 protein promotes the reaction [Ionomycin results in increased abundance of Inositol Phosphates] |
CTD |
PMID:11377826 |
|
NCBI chr 3:122,059,988...122,772,896
Ensembl chr 3:122,060,031...122,772,869
|
|
G |
Pld2 |
phospholipase D2 |
multiple interactions |
ISO |
PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:18423386 |
|
NCBI chr10:55,256,326...55,274,192
Ensembl chr10:55,256,359...55,272,808
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
Ionomycin results in increased expression of PMAIP1 mRNA |
CTD |
PMID:24247028 |
|
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pnpla4 |
patatin like phospholipase domain containing 4 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of PNPLA4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of PNPLA4 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr X:42,313,554...42,318,451
Ensembl chr X:42,305,373...42,318,552
|
|
G |
Pou2f1 |
POU class 2 homeobox 1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of POU2F1 protein |
CTD |
PMID:16241859 |
|
NCBI chr13:78,120,617...78,263,306
Ensembl chr13:78,130,685...78,263,363
|
|
G |
Pou2f2 |
POU class 2 homeobox 2 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of POU2F2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of POU2F2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:80,682,330...80,769,756
Ensembl chr 1:80,685,741...80,724,261
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions increases expression |
EXP |
Cyclosporine inhibits the reaction [Ionomycin results in increased expression of PPARGC1A mRNA]; KN 62 affects the reaction [Ionomycin results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:17516843 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
multiple interactions |
ISO |
PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:23775084 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Ppp2cb |
protein phosphatase 2 catalytic subunit beta |
multiple interactions |
ISO |
PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:23775084 |
|
NCBI chr16:58,558,119...58,579,325
Ensembl chr16:58,558,122...58,579,576
|
|
G |
Prf1 |
perforin 1 |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of PRF1 protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of PRF1 protein |
CTD |
PMID:30171972 |
|
NCBI chr20:29,246,202...29,251,712
Ensembl chr20:29,246,202...29,251,701
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
ISO |
PRKCB protein affects the reaction [[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein] |
CTD |
PMID:37326882 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prkcq |
protein kinase C, theta |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of PRKCQ protein; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of PRKCQ protein] |
CTD |
PMID:16241859 |
|
NCBI chr17:67,246,394...67,379,049
Ensembl chr17:67,246,394...67,378,704
|
|
G |
Psmb10 |
proteasome 20S subunit beta 10 |
multiple interactions |
ISO |
[PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GATA3 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the susceptibility to [Tetradecanoylphorbol Acetate co-treated with Ionomycin] |
CTD |
PMID:22398747 |
|
NCBI chr19:33,830,958...33,833,442
Ensembl chr19:33,827,229...33,833,626
|
|
G |
Psmb8 |
proteasome 20S subunit beta 8 |
multiple interactions |
ISO |
[PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GATA3 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the susceptibility to [Tetradecanoylphorbol Acetate co-treated with Ionomycin] |
CTD |
PMID:22398747 |
|
NCBI chr20:4,652,159...4,655,122
Ensembl chr20:4,652,159...4,655,283
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
multiple interactions |
EXP |
Ionomycin results in increased phosphorylation of and results in increased activity of PTK2B protein |
CTD |
PMID:16877402 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of RBPJ protein |
CTD |
PMID:23134680 |
|
NCBI chr14:57,338,493...57,523,330
Ensembl chr14:57,338,507...57,523,353
|
|
G |
Rcan1 |
regulator of calcineurin 1 |
increases expression |
ISO |
Ionomycin results in increased expression of RCAN1 protein |
CTD |
PMID:12927602 |
|
NCBI chr11:31,622,208...31,702,150
Ensembl chr11:31,622,210...31,702,045
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892
|
|
G |
Rhog |
ras homolog family member G |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of RHOG mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of RHOG mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:156,618,713...156,630,710
Ensembl chr 1:156,615,349...156,631,257
|
|
G |
Rnaset2 |
ribonuclease T2 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of RNASET2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of RNASET2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:52,576,344...52,603,151
Ensembl chr 1:52,585,929...52,603,147
|
|
G |
RT1-Da |
RT1 class II, locus Da |
multiple interactions |
EXP |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of RT1-DA protein |
CTD |
PMID:9536116 |
|
NCBI chr20:4,513,464...4,518,457
Ensembl chr20:4,512,911...4,518,455
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO |
Ionomycin affects the reaction [CALR protein affects the expression of RUNX2 mRNA] |
CTD |
PMID:32220932 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sart1 |
spliceosome associated factor 1, recruiter of U4/U6.U5 tri-snRNP |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SART1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SART1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:202,690,472...202,699,136
Ensembl chr 1:202,690,459...202,699,136
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
EXP |
Ionomycin results in increased expression of SERPINE1 mRNA |
CTD |
PMID:15961275 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sf3b4 |
splicing factor 3B subunit 4 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SF3B4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SF3B4 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 2:183,732,791...183,737,545
Ensembl chr 2:183,732,754...183,737,959
|
|
G |
Sftpb |
surfactant protein B |
increases secretion |
ISO EXP |
Ionomycin results in increased secretion of SFTPB protein |
CTD |
PMID:11704537 PMID:14565945 |
|
NCBI chr 4:104,359,303...104,368,439
Ensembl chr 4:104,359,396...104,368,436
|
|
G |
Sftpc |
surfactant protein C |
increases secretion |
ISO EXP |
Ionomycin results in increased secretion of SFTPC protein |
CTD |
PMID:11704537 PMID:14565945 |
|
NCBI chr15:45,596,565...45,599,615
Ensembl chr15:45,596,574...45,610,777
|
|
G |
Sirt1 |
sirtuin 1 |
increases expression |
EXP |
Ionomycin results in increased expression of SIRT1 protein |
CTD |
PMID:17581637 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sla |
src-like adaptor |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 7:98,534,431...98,584,810
Ensembl chr 7:98,535,368...98,584,648
|
|
G |
Slc39a7 |
solute carrier family 39 member 7 |
multiple interactions |
ISO |
Ionomycin promotes the reaction [EGF protein promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]] |
CTD |
PMID:22317921 |
|
NCBI chr20:4,823,166...4,826,538
Ensembl chr20:4,822,012...4,826,537
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLC3A2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLC3A2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
SOD2 protein results in decreased susceptibility to [Tetradecanoylphorbol Acetate co-treated with Ionomycin] |
CTD |
PMID:22429591 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
multiple interactions |
ISO |
Ionomycin affects the reaction [CALR protein affects the expression of SOX9 mRNA] |
CTD |
PMID:32220932 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sp7 |
Sp7 transcription factor |
multiple interactions |
ISO |
Ionomycin affects the reaction [CALR protein affects the expression of SP7 mRNA] |
CTD |
PMID:32220932 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Srpra |
SRP receptor subunit alpha |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SRPRA mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SRPRA mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 8:33,560,365...33,566,458
Ensembl chr 8:33,560,348...33,566,470
|
|
G |
Stim1 |
stromal interaction molecule 1 |
multiple interactions |
ISO |
[Thapsigargin co-treated with Ionomycin] promotes the reaction [STIM1 protein binds to ATP2A3 protein] |
CTD |
PMID:18439569 |
|
NCBI chr 1:156,656,246...156,818,777
Ensembl chr 1:156,656,013...156,818,363
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions increases phosphorylation |
ISO |
STO 609 inhibits the reaction [Ionomycin results in increased phosphorylation of STK11 protein] |
CTD |
PMID:33124469 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Syn1 |
synapsin I |
affects response to substance |
ISO |
SYN1 protein affects the susceptibility to Ionomycin |
CTD |
PMID:22759588 |
|
NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396
|
|
G |
Tbx21 |
T-box transcription factor 21 |
multiple interactions |
ISO |
[PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA] |
CTD |
PMID:22398747 |
|
NCBI chr10:82,082,322...82,098,831
Ensembl chr10:82,082,322...82,098,831
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
EXP |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TFRC protein |
CTD |
PMID:9766631 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TGFB1 mRNA |
CTD |
PMID:18434080 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in decreased expression of MIR146A mRNA; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of MIR27A mRNA; [Ionomycin co-treated with IL1A protein] results in increased secretion of TNF protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF protein]; Diclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; hydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; Ionomycin inhibits the reaction [[N-(4-hydroxyphenyl)arachidonylamide co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF protein]; NECAME_02783 protein modified form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; Peptides inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; PRKCB protein affects the reaction [[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA; benzamide inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA]; phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA] [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein; Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF mRNA] |
CTD |
PMID:10820229 PMID:10890505 PMID:12411406 PMID:15358692 PMID:16154495 PMID:17196940 PMID:17572062 PMID:17685462 PMID:18434080 PMID:19277450 PMID:21075198 PMID:22398747 PMID:25073960 PMID:29777833 PMID:31958493 PMID:34051231 PMID:37326882 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TNFRSF1B mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TNFRSF1B mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|
G |
Tnfrsf4 |
TNF receptor superfamily member 4 |
multiple interactions increases expression |
EXP |
Cyclosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]]; Cyclosporine inhibits the reaction [Ionomycin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNFRSF4 protein]]; Cyclosporine inhibits the reaction [Ionomycin results in increased expression of TNFRSF4 protein]; IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]; Ionomycin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNFRSF4 protein]; Staurosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]]; Staurosporine inhibits the reaction [Ionomycin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNFRSF4 protein]] |
CTD |
PMID:9766631 |
|
NCBI chr 5:166,606,909...166,609,599
Ensembl chr 5:166,606,909...166,609,599
|
|
G |
Tnfsf9 |
TNF superfamily member 9 |
multiple interactions |
ISO |
[Ionomycin co-treated with Phorbol Esters] promotes the reaction [entinostat results in increased expression of TNFSF9 mRNA]; [Ionomycin co-treated with Phorbol Esters] promotes the reaction [trichostatin A results in increased expression of TNFSF9 mRNA]; [Ionomycin co-treated with Phorbol Esters] promotes the reaction [vorinostat results in increased expression of TNFSF9 mRNA] |
CTD |
PMID:19759901 |
|
NCBI chr 9:1,944,017...1,946,351
Ensembl chr 9:1,944,017...1,946,345
|
|
G |
Tnpo1 |
transportin 1 |
increases expression |
ISO |
Ionomycin results in increased expression of TNPO1 mRNA |
CTD |
PMID:10843682 |
|
NCBI chr 2:30,207,529...30,300,162
Ensembl chr 2:30,211,510...30,300,375
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
|
|
G |
Trib2 |
tribbles pseudokinase 2 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TRIB2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TRIB2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370
|
|
G |
Trpm4 |
transient receptor potential cation channel, subfamily M, member 4 |
multiple interactions increases activity |
ISO |
[Ionomycin co-treated with Calcium co-treated with CAMK2D protein] results in increased activity of TRPM4 protein Ionomycin results in increased activity of TRPM4 protein |
CTD |
PMID:25047048 PMID:33392831 |
|
NCBI chr 1:95,781,805...95,812,095
Ensembl chr 1:95,782,000...95,812,532
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases activity |
ISO EXP |
Ionomycin promotes the reaction [Calcium Chloride inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]] Ionomycin results in increased activity of TRPV1 protein Ionomycin inhibits the reaction [Calcium Chloride results in increased activity of TRPV1 protein]; Ionomycin inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]] |
CTD |
PMID:11606325 PMID:19553475 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Trpv3 |
transient receptor potential cation channel, subfamily V, member 3 |
increases activity |
EXP |
Ionomycin results in increased activity of TRPV3 protein |
CTD |
PMID:21726418 |
|
NCBI chr10:57,883,546...57,915,865
Ensembl chr10:57,883,546...57,913,296
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
increases activity |
EXP |
Ionomycin results in increased activity of TRPV4 protein |
CTD |
PMID:21726418 |
|
NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517
|
|
G |
Txnip |
thioredoxin interacting protein |
decreases expression |
ISO |
Ionomycin results in decreased expression of TXNIP mRNA |
CTD |
PMID:10843682 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Tyrobp |
transmembrane immune signaling adaptor Tyrobp |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:85,672,931...85,676,856
Ensembl chr 1:85,672,994...85,676,848
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of VIM mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of VIM mRNA |
CTD |
PMID:15477007 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [deoxynivalenol results in decreased expression of ZEB1 protein] |
CTD |
PMID:11893416 |
|
NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
|
|
|
G |
Abca13 |
ATP binding cassette subfamily A member 13 |
decreases expression |
ISO |
kojic acid results in decreased expression of ABCA13 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr14:83,873,397...84,376,138
Ensembl chr14:83,873,940...84,375,075
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in increased expression of ABCC2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in decreased expression of ABCC2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
multiple interactions |
ISO EXP |
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of ABCC6 mRNA [Diethylnitrosamine co-treated with kojic acid] results in decreased expression of ABCC6 mRNA |
CTD |
PMID:17917374 PMID:18544905 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of ABCC9 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
|
|
G |
Abcd1 |
ATP binding cassette subfamily D member 1 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of ABCD1 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr X:151,428,334...151,450,115
Ensembl chr X:151,428,578...151,450,115
|
|
G |
Abcf2 |
ATP binding cassette subfamily F member 2 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of ABCF2 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 4:10,594,802...10,607,620
Ensembl chr 4:10,594,907...10,607,606
|
|
G |
Abhd1 |
abhydrolase domain containing 1 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of ABHD1 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 6:25,422,526...25,427,514
Ensembl chr 6:25,422,526...25,427,514
|
|
G |
Acer3 |
alkaline ceramidase 3 |
increases expression |
ISO |
kojic acid results in increased expression of ACER3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:152,504,180...152,606,596
Ensembl chr 1:152,504,186...152,606,591
|
|
G |
Acmsd |
aminocarboxymuconate semialdehyde decarboxylase |
decreases expression |
ISO |
kojic acid results in decreased expression of ACMSD mRNA |
CTD |
PMID:16595896 |
|
NCBI chr13:39,200,412...39,245,954
Ensembl chr13:39,200,314...39,245,209
|
|
G |
Acvrl1 |
activin A receptor like type 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of ACVRL1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 7:132,239,200...132,256,592
Ensembl chr 7:132,239,729...132,256,591
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
decreases expression |
ISO |
kojic acid results in decreased expression of ADRB3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Agap3 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 3 |
increases expression |
ISO |
kojic acid results in increased expression of AGAP3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 4:10,674,746...10,724,848
Ensembl chr 4:10,674,064...10,725,244
|
|
G |
Agbl4 |
AGBL carboxypeptidase 4 |
decreases expression |
ISO |
kojic acid results in decreased expression of AGBL4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:125,254,963...126,534,367
Ensembl chr 5:125,254,956...126,534,367
|
|
G |
Ahnak |
AHNAK nucleoprotein |
decreases expression |
ISO |
kojic acid results in decreased expression of AHNAK mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of AKT1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alpi |
alkaline phosphatase, intestinal |
decreases expression |
ISO |
kojic acid results in decreased expression of ALPI mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 9:87,773,411...87,776,877
Ensembl chr 9:87,773,411...87,776,877
|
|
G |
Amtn |
amelotin |
decreases expression |
ISO |
kojic acid results in decreased expression of AMTN mRNA |
CTD |
PMID:16595896 |
|
NCBI chr14:19,648,624...19,661,181
Ensembl chr14:19,648,625...19,661,181
|
|
G |
Anxa1 |
annexin A1 |
decreases expression |
ISO |
kojic acid results in decreased expression of ANXA1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Anxa5 |
annexin A5 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ANXA5 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Ap1s1 |
adaptor related protein complex 1 subunit sigma 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of AP1S1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713
|
|
G |
Apobec1 |
apolipoprotein B mRNA editing enzyme catalytic subunit 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of APOBEC1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 4:155,800,030...155,828,515
Ensembl chr 4:155,800,887...155,827,390
|
|
G |
App |
amyloid beta precursor protein |
increases expression |
ISO |
kojic acid results in increased expression of APP mRNA |
CTD |
PMID:16595896 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aptx |
aprataxin |
decreases expression |
ISO |
kojic acid results in decreased expression of APTX mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:55,798,896...55,822,963
Ensembl chr 5:55,800,248...55,822,855
|
|
G |
Aqp1 |
aquaporin 1 |
increases expression |
ISO |
kojic acid results in increased expression of AQP1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Arfip2 |
ADP-ribosylation factor interacting protein 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of ARFIP2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:159,974,255...159,980,398
Ensembl chr 1:159,974,201...159,980,336
|
|
G |
Arhgef16 |
Rho guanine nucleotide exchange factor 16 |
decreases expression |
ISO |
kojic acid results in decreased expression of ARHGEF16 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:164,843,656...164,866,212
Ensembl chr 5:164,844,161...164,866,212
|
|
G |
Arl6ip5 |
ADP-ribosylation factor like GTPase 6 interacting protein 5 |
increases expression |
ISO |
kojic acid results in increased expression of ARL6IP5 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608
|
|
G |
Asnsd1 |
asparagine synthetase domain containing 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of ASNSD1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 9:48,126,808...48,139,073
Ensembl chr 9:48,126,808...48,139,073
|
|
G |
Atf6b |
activating transcription factor 6 beta |
decreases expression |
ISO |
kojic acid results in decreased expression of ATF6B mRNA |
CTD |
PMID:16595896 |
|
NCBI chr20:4,090,921...4,098,920
Ensembl chr20:4,090,921...4,098,894
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ATM mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
B4galnt4 |
beta-1,4-N-acetyl-galactosaminyl transferase 4 |
decreases expression |
ISO |
kojic acid results in decreased expression of B4GALNT4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:196,171,394...196,182,294
Ensembl chr 1:196,171,394...196,182,294
|
|
G |
Bag5 |
BAG cochaperone 5 |
decreases expression |
ISO |
kojic acid results in decreased expression of BAG5 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 6:130,768,467...130,772,122
Ensembl chr 6:130,768,141...130,772,970
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
increases expression |
ISO |
kojic acid results in increased expression of BCL2A1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of BCL2L2 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of BIRC2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Bmp5 |
bone morphogenetic protein 5 |
decreases expression |
ISO |
kojic acid results in decreased expression of BMP5 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925
|
|
G |
Brsk1 |
BR serine/threonine kinase 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of BRSK1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:69,134,166...69,159,947
Ensembl chr 1:69,134,565...69,160,365
|
|
G |
Bst2 |
bone marrow stromal cell antigen 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of BST2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr16:18,216,605...18,220,979
Ensembl chr16:18,217,407...18,220,979
|
|
G |
C19h1orf131 |
similar to human chromosome 1 open reading frame 131 |
decreases expression |
ISO |
kojic acid results in decreased expression of C1ORF131 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr19:52,807,932...52,822,259
Ensembl chr19:52,807,934...52,822,267
|
|
G |
C2h1orf54 |
similar to human chromosome 1 open reading frame 54 |
increases expression |
ISO |
kojic acid results in increased expression of C1ORF54 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:183,424,989...183,434,713
Ensembl chr 2:183,424,984...183,435,089
|
|
G |
C5h1orf87 |
similar to human chromosome 1 open reading frame 87 |
decreases expression |
ISO |
kojic acid results in decreased expression of C1ORF87 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:111,342,381...111,411,576
Ensembl chr 5:111,342,387...111,411,590
|
|
G |
Cab39l |
calcium binding protein 39-like |
increases expression |
ISO |
kojic acid results in increased expression of CAB39L mRNA |
CTD |
PMID:16595896 |
|
NCBI chr15:33,606,588...33,710,518
Ensembl chr15:33,606,694...33,743,545
|
|
G |
Calr |
calreticulin |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CALR mRNA |
CTD |
PMID:18544905 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Car13 |
carbonic anhydrase 13 |
increases expression |
ISO |
kojic acid results in increased expression of CAR13 mRNA |
CTD |
PMID:19000923 |
|
NCBI chr 2:86,928,401...86,959,525
Ensembl chr 2:86,928,383...86,959,525
|
|
G |
Car14 |
carbonic anhydrase 14 |
increases expression |
ISO |
kojic acid results in increased expression of CA14 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:183,442,263...183,449,231
Ensembl chr 2:183,441,667...183,449,693
|
|
G |
Casp4 |
caspase 4 |
multiple interactions |
EXP |
[kojic acid co-treated with Diethylnitrosamine] results in increased expression of CASP4 mRNA; Ascorbic Acid inhibits the reaction [[kojic acid co-treated with Diethylnitrosamine] results in increased expression of CASP4 mRNA] |
CTD |
PMID:18544905 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CASP8 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CAT mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
increases expression |
ISO |
kojic acid results in increased expression of CCAR1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526
|
|
G |
Ccdc50 |
coiled-coil domain containing 50 |
increases expression |
ISO |
kojic acid results in increased expression of CCDC50 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr11:73,332,798...73,395,333
Ensembl chr11:73,334,248...73,395,150
|
|
G |
Ccl21 |
C-C motif chemokine ligand 21 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCL21A mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 5:56,980,557...56,981,661
Ensembl chr 5:56,980,558...56,981,686
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCL3 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccnb1 |
cyclin B1 |
increases expression |
ISO |
kojic acid results in increased expression of CCNB1 mRNA |
CTD |
PMID:19000923 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnc |
cyclin C |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCNC mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 5:35,266,828...35,284,943
Ensembl chr 5:35,266,823...35,296,584
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
EXP ISO |
[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of CCND1 mRNA [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCND1 mRNA |
CTD |
PMID:17917374 PMID:18544905 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
EXP ISO |
[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in increased expression of CCNG1 mRNA [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCNG1 mRNA |
CTD |
PMID:17917374 PMID:18544905 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Ccpg1 |
cell cycle progression 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of CCPG1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
decreases expression |
ISO |
kojic acid results in decreased expression of CCR4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056
|
|
G |
Cd22 |
CD22 molecule |
decreases expression |
ISO |
kojic acid results in decreased expression of CD22 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:86,116,376...86,132,782
Ensembl chr 1:86,117,459...86,132,322
|
|
G |
Cd274 |
CD274 molecule |
increases expression |
ISO |
kojic acid results in increased expression of CD274 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd3g |
CD3 gamma subunit of T-cell receptor complex |
decreases expression |
ISO |
kojic acid results in decreased expression of CD3G mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:45,280,797...45,287,271
Ensembl chr 8:45,281,204...45,287,147
|
|
G |
Cdin1 |
CDAN1 interacting nuclease 1 |
increases expression |
ISO |
kojic acid results in increased expression of CDIN1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:102,441,553...102,646,935
Ensembl chr 3:102,441,704...102,646,682
|
|
G |
Cdk10 |
cyclin-dependent kinase 10 |
decreases expression |
ISO |
kojic acid results in decreased expression of CDK10 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr19:51,260,012...51,273,009
Ensembl chr19:51,261,356...51,269,078
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CDKN1A mRNA [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CDKN1A mRNA |
CTD |
PMID:17917374 PMID:18544905 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CDKN1B mRNA; [Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CDKN1B mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of CEACAM1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression |
ISO |
kojic acid results in increased expression of CEBPD mRNA |
CTD |
PMID:16595896 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Cenpq |
centromere protein Q |
decreases expression |
ISO |
kojic acid results in decreased expression of CENPQ mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 9:19,957,122...19,972,807
Ensembl chr 9:19,957,048...19,972,789
|
|
G |
Cep192 |
centrosomal protein 192 |
increases expression |
ISO |
kojic acid results in increased expression of CEP192 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr18:61,373,937...61,458,405
Ensembl chr18:61,332,158...61,458,379
|
|
G |
Cep72 |
centrosomal protein 72 |
increases expression |
ISO |
kojic acid results in increased expression of CEP72 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:29,225,312...29,255,294
Ensembl chr 1:29,225,361...29,255,271
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of CES1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
EXP |
[kojic acid co-treated with Diethylnitrosamine] results in increased expression of CHEK2 mRNA; Ascorbic Acid inhibits the reaction [[kojic acid co-treated with Diethylnitrosamine] results in increased expression of CHEK2 mRNA] |
CTD |
PMID:18544905 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
chromosome 12 open reading frame 4 |
similar to human |
decreases expression |
ISO |
kojic acid results in decreased expression of C12ORF4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 4:159,772,693...159,809,322
Ensembl chr 4:159,772,786...159,806,382
|
|
G |
Chst4 |
carbohydrate sulfotransferase 4 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of CHST4 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr19:37,993,471...38,002,123
Ensembl chr19:37,991,417...38,003,608
|
|
G |
Cibar1 |
CBY1 interacting BAR domain containing 1 |
increases expression |
ISO |
kojic acid results in increased expression of CIBAR1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:25,613,993...25,632,440
Ensembl chr 5:25,614,033...25,632,489
|
|
G |
Cldn3 |
claudin 3 |
decreases expression |
ISO |
kojic acid results in decreased expression of CLDN3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr12:21,708,538...21,710,010
Ensembl chr12:21,708,398...21,711,001
|
|
G |
Cldnd2 |
claudin domain containing 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of CLDND2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:93,848,533...93,851,693
Ensembl chr 1:93,848,533...93,851,217
|
|
G |
Clec4b2 |
C-type lectin domain family 4, member B2 |
decreases expression |
ISO |
kojic acid results in decreased expression of CLEC4C mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 4:156,462,742...156,486,240
Ensembl chr 4:156,462,742...156,486,240
|
|
G |
Clmp |
CXADR-like membrane protein |
decreases expression |
ISO |
kojic acid results in decreased expression of CLMP mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:41,060,527...41,168,841
Ensembl chr 8:41,060,799...41,168,838
|
|
G |
Clu |
clusterin |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CLU mRNA |
CTD |
PMID:18544905 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cnih1 |
cornichon family AMPA receptor auxiliary protein 1 |
increases expression |
ISO |
kojic acid results in increased expression of CNIH1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr15:20,037,885...20,049,857
Ensembl chr15:20,037,885...20,049,761
|
|
G |
Cnksr2 |
connector enhancer of kinase suppressor of Ras 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of CNKSR2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr X:36,908,135...37,148,337
Ensembl chr X:36,907,850...37,150,555
|
|
G |
Col17a1 |
collagen type XVII alpha 1 chain |
decreases expression |
ISO |
kojic acid results in decreased expression of COL17A1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:246,530,589...246,577,559
Ensembl chr 1:246,531,367...246,577,632
|
|
G |
Col24a1 |
collagen type XXIV alpha 1 chain |
decreases expression |
ISO |
kojic acid results in decreased expression of COL24A1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:234,212,256...234,469,445
Ensembl chr 2:234,212,324...234,469,441
|
|
G |
Colq |
collagen like tail subunit of asymmetric acetylcholinesterase |
increases expression |
ISO |
kojic acid results in increased expression of COLQ mRNA |
CTD |
PMID:16595896 |
|
NCBI chr16:6,731,850...6,824,973
Ensembl chr16:6,731,858...6,787,107
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of COMT mRNA |
CTD |
PMID:18544905 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cops2 |
COP9 signalosome subunit 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of COPS2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:113,084,174...113,110,090
Ensembl chr 3:113,084,176...113,109,947
|
|
G |
Coq10a |
coenzyme Q10A |
increases expression |
ISO |
kojic acid results in increased expression of COQ10A mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 7:792,089...798,392
Ensembl chr 7:792,089...800,161
|
|
G |
Coq8a |
coenzyme Q8A |
increases expression |
ISO |
kojic acid results in increased expression of COQ8A mRNA |
CTD |
PMID:16595896 |
|
NCBI chr13:91,904,731...91,933,588
Ensembl chr13:91,904,739...91,931,431
|
|
G |
Cpb1 |
carboxypeptidase B1 |
decreases expression |
ISO |
kojic acid results in decreased expression of CPB1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:102,755,241...102,785,628
Ensembl chr 2:102,755,241...102,785,628
|
|
G |
Cpe |
carboxypeptidase E |
increases expression |
ISO |
kojic acid results in increased expression of CPE mRNA |
CTD |
PMID:16595896 |
|
NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
|
|
G |
Cpne5 |
copine 5 |
increases expression |
ISO |
kojic acid results in increased expression of CPNE5 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr20:7,206,742...7,289,309
Ensembl chr20:7,206,742...7,288,883
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
decreases phosphorylation |
ISO |
kojic acid results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:27586645 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cse1l |
chromosome segregation 1 like |
decreases expression |
ISO |
kojic acid results in decreased expression of CSE1L mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:155,641,104...155,678,866
Ensembl chr 3:155,641,166...155,678,865
|
|
G |
Ctnnal1 |
catenin alpha-like 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of CTNNAL1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:71,514,340...71,569,431
Ensembl chr 5:71,514,340...71,569,431
|
|
G |
Ctsz |
cathepsin Z |
increases expression |
ISO |
kojic acid results in increased expression of CTSZ mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:163,224,875...163,235,645
Ensembl chr 3:163,224,875...163,235,645
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYB5R3 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYB5R3 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
increases expression |
ISO |
kojic acid results in increased expression of CYP26B1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
|
|
G |
Cyp2b15 |
cytochrome P450, family 2, subfamily b, polypeptide 15 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2B15 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYP2B15 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 1:82,094,188...82,106,492
Ensembl chr 1:82,094,180...82,106,492
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CYP2B10 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2C mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c13 |
cytochrome P450, family 2, subfamily c, polypeptide 13 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2C13 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 1:238,786,764...238,867,195
Ensembl chr 1:238,786,765...238,867,191
|
|
G |
Cyp2c7 |
cytochrome P450, family 2, subfamily c, polypeptide 7 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2C7 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 1:237,332,641...237,388,714
Ensembl chr 1:237,332,659...237,388,709
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2D22 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYP2D22 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2F2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYP2F2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 1:82,416,107...82,429,897
Ensembl chr 1:82,416,130...82,429,896
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP4A22 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYP4A22 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Cyp4b1 |
cytochrome P450, family 4, subfamily b, polypeptide 1 |
multiple interactions |
ISO EXP |
[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of CYP4B1 mRNA [Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP4B1 mRNA |
CTD |
PMID:17917374 PMID:18544905 |
|
NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348
|
|
G |
Cyp4f1 |
cytochrome P450, family 4, subfamily f, polypeptide 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP4F2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CYP7A1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYP7A1 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Cyth3 |
cytohesin 3 |
increases expression |
ISO |
kojic acid results in increased expression of CYTH3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr12:10,840,137...10,933,792
Ensembl chr12:10,840,157...10,933,812
|
|
G |
Cytip |
cytohesin 1 interacting protein |
increases expression |
ISO |
kojic acid results in increased expression of CYTIP mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:42,698,058...42,774,955
Ensembl chr 3:42,698,768...42,725,993
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
increases expression |
ISO |
kojic acid results in increased expression of DAGLA mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G |
Dazap2 |
DAZ associated protein 2 |
increases expression |
ISO |
kojic acid results in increased expression of DAZAP2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 7:131,714,749...131,720,266
Ensembl chr 7:131,714,745...131,720,265
|
|
G |
Dcaf13 |
DDB1 and CUL4 associated factor 13 |
decreases expression |
ISO |
kojic acid results in decreased expression of DCAF13 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 7:70,160,983...70,196,142
Ensembl chr 7:70,160,941...70,196,142
|
|
G |
Dct |
dopachrome tautomerase |
decreases expression |
ISO |
kojic acid results in decreased expression of DCT protein |
CTD |
PMID:27586645 |
|
NCBI chr15:95,062,006...95,100,863
Ensembl chr15:95,062,003...95,100,836
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of DDIT3 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dek |
DEK proto-oncogene |
decreases expression |
ISO |
kojic acid results in decreased expression of DEK mRNA |
CTD |
PMID:16595896 |
|
NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
|
|
G |
Dlgap4 |
DLG associated protein 4 |
increases expression |
ISO |
kojic acid results in increased expression of DLGAP4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:145,124,189...145,271,791
Ensembl chr 3:145,175,479...145,270,490
|
|
G |
Dlx1 |
distal-less homeobox 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of DLX1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:56,356,190...56,360,780
Ensembl chr 3:56,356,190...56,360,780
|
|
G |
Dmxl1 |
Dmx-like 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of DMXL1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr18:42,993,292...43,163,457
Ensembl chr18:42,993,340...43,163,456
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of DNAJA1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967
|
|
G |
Dnaja2 |
DnaJ heat shock protein family (Hsp40) member A2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of DNAJA2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of DNAJA2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr19:21,497,792...21,516,904
Ensembl chr19:21,497,729...21,516,901
|
|
G |
Dnttip2 |
deoxynucleotidyltransferase, terminal, interacting protein 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of DNTTIP2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:210,374,321...210,386,366
Ensembl chr 2:210,374,289...210,385,581
|
|
G |
Dock4 |
dedicator of cytokinesis 4 |
increases expression |
ISO |
kojic acid results in increased expression of DOCK4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 6:57,512,929...57,902,597
Ensembl chr 6:57,512,908...57,901,855
|
|
G |
Dok4 |
docking protein 4 |
decreases expression |
ISO |
kojic acid results in decreased expression of DOK4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr19:10,146,520...10,157,187
Ensembl chr19:10,146,474...10,158,203
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of DPYD mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
|
|
G |
Dspp |
dentin sialophosphoprotein |
decreases expression |
ISO |
kojic acid results in decreased expression of DSPP mRNA |
CTD |
PMID:16595896 |
|
NCBI chr14:5,565,562...5,571,669
Ensembl chr14:5,565,629...5,571,672
|
|
G |
Dstn |
destrin, actin depolymerizing factor |
increases expression |
ISO |
kojic acid results in increased expression of DSTN mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:131,284,647...131,311,361
Ensembl chr 3:131,284,648...131,311,379
|
|
G |
Dynlt3 |
dynein light chain Tctex-type 3 |
decreases expression |
ISO |
kojic acid results in decreased expression of DYNLT3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr X:13,327,933...13,337,139
Ensembl chr X:13,327,892...13,337,139
|
|
G |
E2f3 |
E2F transcription factor 3 |
increases expression |
ISO |
kojic acid results in increased expression of E2F3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr17:34,601,756...34,679,139
Ensembl chr17:34,601,830...34,676,253
|
|
G |
E2f8 |
E2F transcription factor 8 |
increases expression |
ISO |
kojic acid results in increased expression of E2F8 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Efna3 |
ephrin A3 |
decreases expression |
ISO |
kojic acid results in decreased expression of EFNA3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:174,729,192...174,738,111
Ensembl chr 2:174,729,764...174,738,736
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in increased expression of EGR1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
decreases expression |
ISO |
kojic acid results in decreased expression of EIF4E mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Eif5a2 |
eukaryotic translation initiation factor 5A2 |
increases expression |
ISO |
kojic acid results in increased expression of EIF5A2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:111,728,587...111,746,087
Ensembl chr 2:111,729,323...111,746,087
|
|
G |
Elane |
elastase, neutrophil expressed |
decreases expression |
ISO |
kojic acid results in decreased expression of ELANE mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100
|
|
G |
Ep300 |
E1A binding protein p300 |
increases expression |
ISO |
kojic acid results in increased expression of EP300 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Epha10 |
EPH receptor A10 |
decreases expression |
ISO |
kojic acid results in decreased expression of EPHA10 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:137,139,588...137,175,637
Ensembl chr 5:137,140,735...137,174,157
|
|
G |
Epha4 |
Eph receptor A4 |
increases expression |
ISO |
kojic acid results in increased expression of EPHA4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 9:78,815,460...78,958,139
Ensembl chr 9:78,815,460...78,958,139
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of EPHX1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of EPHX1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of EPHX2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of EPHX2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Ercc2 |
ERCC excision repair 2, TFIIH core complex helicase subunit |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC2 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102
|
|
G |
Ercc3 |
ERCC excision repair 3, TFIIH core complex helicase subunit |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of ERCC3 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr18:23,883,613...23,914,326
Ensembl chr18:23,883,580...23,914,329
|
|
G |
Ercc4 |
ERCC excision repair 4, endonuclease catalytic subunit |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC4 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
|
|
G |
Ercc5 |
ERCC excision repair 5, endonuclease |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC5 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472
|
|
G |
Esam |
endothelial cell adhesion molecule |
increases expression |
ISO |
kojic acid results in increased expression of ESAM mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:37,238,228...37,249,217
Ensembl chr 8:37,238,287...37,249,215
|
|
G |
Esrp1 |
epithelial splicing regulatory protein 1 |
increases expression |
ISO |
kojic acid results in increased expression of ESRP1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:24,427,611...24,482,157
Ensembl chr 5:24,428,717...24,482,062
|
|
G |
Exd1 |
exonuclease 3'-5' domain containing 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of EXD1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:106,507,839...106,535,922
Ensembl chr 3:106,508,076...106,535,922
|
|
G |
Exoc2 |
exocyst complex component 2 |
increases expression |
ISO |
kojic acid results in increased expression of EXOC2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr17:33,506,289...33,698,246
Ensembl chr17:33,506,338...33,693,289
|
|
G |
F10 |
coagulation factor X |
increases expression |
ISO |
kojic acid results in increased expression of F10 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
Fam241a |
family with sequence similarity 241 member A |
increases expression |
ISO |
kojic acid results in increased expression of FAM241A mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:216,344,563...216,375,193
Ensembl chr 2:216,343,822...216,375,242
|
|
G |
Fbn2 |
fibrillin 2 |
increases expression |
ISO |
kojic acid results in increased expression of FBN2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr18:51,499,670...51,703,976
Ensembl chr18:51,499,737...51,703,976
|
|
G |
Fbxo16 |
F-box protein 16 |
increases expression |
ISO |
kojic acid results in increased expression of FBXO16 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr15:39,492,268...39,541,493
Ensembl chr15:39,492,377...39,541,480
|
|
G |
Fgf12 |
fibroblast growth factor 12 |
increases expression |
ISO |
kojic acid results in increased expression of FGF12 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr11:71,997,151...72,564,757
Ensembl chr11:71,997,099...72,562,607
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
decreases expression |
ISO |
kojic acid results in decreased expression of FGF5 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr14:11,323,827...11,346,164
Ensembl chr14:11,325,334...11,345,997
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
decreases expression |
ISO |
kojic acid results in decreased expression of FGFR3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fibcd1 |
fibrinogen C domain containing 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of FIBCD1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:15,092,682...15,126,371
Ensembl chr 3:15,092,681...15,126,399
|
|
G |
Fkbp10 |
FKBP prolyl isomerase 10 |
increases expression |
ISO |
kojic acid results in increased expression of FKBP10 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr10:85,345,434...85,357,998
Ensembl chr10:85,346,126...85,427,330
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of FMO1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of FMO1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
Fpgt |
fucose-1-phosphate guanylyltransferase |
decreases expression |
ISO |
kojic acid results in decreased expression of FPGT mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:244,099,031...244,119,967
Ensembl chr 2:244,099,076...244,119,899
|
|
G |
Frmpd4 |
FERM and PDZ domain containing 4 |
decreases expression |
ISO |
kojic acid results in decreased expression of FRMPD4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr X:25,853,849...26,814,642
Ensembl chr X:25,853,934...26,814,637
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
ISO |
kojic acid results in increased expression of FTH1 mRNA; kojic acid results in increased expression of FTH1 protein |
CTD |
PMID:23738040 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Fzd8 |
frizzled class receptor 8 |
increases expression |
ISO |
kojic acid results in increased expression of FZD8 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr17:57,312,924...57,320,551
Ensembl chr17:57,314,450...57,320,650
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GADD45B mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Galnt1 |
polypeptide N-acetylgalactosaminyltransferase 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of GALNT1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr18:15,489,015...15,568,849
Ensembl chr18:15,489,020...15,568,245
|
|
G |
Gfod1 |
Gfo/Idh/MocA-like oxidoreductase domain containing 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of GFOD1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr17:21,400,142...21,504,972
Ensembl chr17:21,399,479...21,499,938
|
|
G |
Gle1 |
GLE1 RNA export mediator |
decreases expression |
ISO |
kojic acid results in decreased expression of GLE1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:13,209,312...13,237,018
Ensembl chr 3:13,209,322...13,237,379
|
|
G |
Gmpr |
guanosine monophosphate reductase |
decreases expression |
ISO |
kojic acid results in decreased expression of GMPR mRNA |
CTD |
PMID:16595896 |
|
NCBI chr17:19,151,820...19,189,626
Ensembl chr17:19,151,815...19,189,621
|
|
G |
Gnb1 |
G protein subunit beta 1 |
increases expression |
ISO |
kojic acid results in increased expression of GNB1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:166,075,508...166,142,223
Ensembl chr 5:166,075,629...166,142,124
|
|
G |
Gpr146 |
G protein-coupled receptor 146 |
decreases expression |
ISO |
kojic acid results in decreased expression of GPR146 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr12:15,251,936...15,267,217
Ensembl chr12:15,251,813...15,267,206
|
|
G |
Gpr26 |
G protein-coupled receptor 26 |
decreases expression |
ISO |
kojic acid results in decreased expression of GPR26 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:186,766,001...186,805,435
Ensembl chr 1:186,767,062...186,784,568
|
|
G |
Gpr32 |
G protein-coupled receptor 32 |
increases expression |
ISO |
kojic acid results in increased expression of GPR32 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:94,756,863...94,757,895
|
|
G |
Gpr61 |
G protein-coupled receptor 61 |
decreases expression |
ISO |
kojic acid results in decreased expression of GPR61 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:195,781,931...195,789,798
Ensembl chr 2:195,782,752...195,789,621
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GPX1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GPX1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsdma |
gasdermin A |
decreases expression |
ISO |
kojic acid results in decreased expression of GSDMA mRNA |
CTD |
PMID:16595896 |
|
NCBI chr10:83,614,336...83,639,543
Ensembl chr10:83,627,051...83,639,543
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of GSR mRNA |
CTD |
PMID:17917374 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GSTA2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTA2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GSTA3 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTA3 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTA4 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GSTM1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTM1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GSTM2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTM2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions |
ISO EXP |
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTM3 mRNA [Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GSTM3 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTM3 mRNA |
CTD |
PMID:17917374 PMID:18544905 |
|
NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Gucy1a2 |
guanylate cyclase 1 soluble subunit alpha 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of GUCY1A2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:500,212...900,201
Ensembl chr 8:500,212...889,203
|
|
G |
H1f1 |
H1.1 linker histone, cluster member |
increases expression |
ISO |
kojic acid results in increased expression of H1-1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr17:41,366,268...41,367,011
Ensembl chr17:41,366,268...41,367,011
|
|
G |
Hand1 |
heart and neural crest derivatives expressed 1 |
increases expression |
ISO |
kojic acid results in increased expression of HAND1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr10:42,006,646...42,009,213
Ensembl chr10:42,006,651...42,009,213
|
|
G |
Harbi1 |
harbinger transposase derived 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of HARBI1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:77,681,431...77,689,749
Ensembl chr 3:77,681,431...77,689,724
|
|
G |
Hibch |
3-hydroxyisobutyryl-CoA hydrolase |
decreases expression |
ISO |
kojic acid results in decreased expression of HIBCH mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 9:48,590,097...48,669,896
Ensembl chr 9:48,590,099...48,669,824
|
|
G |
Hint3 |
histidine triad nucleotide binding protein 3 |
increases expression |
ISO |
kojic acid results in increased expression of HINT3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:27,035,936...27,045,799
Ensembl chr 1:27,035,905...27,047,721
|
|
G |
Hip1 |
huntingtin interacting protein 1 |
increases expression |
ISO |
kojic acid results in increased expression of HIP1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr12:21,133,364...21,267,796
Ensembl chr12:21,133,406...21,267,725
|
|
G |
Hist1h2al1 |
histone cluster 1 H2A family like 1 |
increases expression |
ISO |
kojic acid results in increased expression of H2AC6 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr17:42,707,954...42,708,420
|
|
G |
Hlf |
HLF transcription factor, PAR bZIP family member |
decreases expression |
ISO |
kojic acid results in decreased expression of HLF mRNA |
CTD |
PMID:16595896 |
|
NCBI chr10:75,154,244...75,211,884
Ensembl chr10:75,154,507...75,211,935
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
decreases expression |
ISO |
kojic acid results in decreased expression of HMMR mRNA |
CTD |
PMID:16595896 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Hmox2 |
heme oxygenase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HMOX2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148
|
|
G |
Hnrnph2 |
heterogeneous nuclear ribonucleoprotein H2 |
increases expression |
ISO |
kojic acid results in increased expression of HNRNPH2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr X:97,780,890...97,786,846
Ensembl chr X:97,780,785...97,787,041
|
|
G |
Hps3 |
HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of HPS3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:102,484,574...102,527,580
Ensembl chr 2:102,484,574...102,526,047
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSP90AA1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSP90AB1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of HSP90AB1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSPA1A mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of HSPA1A mRNA |
CTD |
PMID:18544905 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSPA5 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSPB1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSPD1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
multiple interactions |
EXP ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSPE1 mRNA [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of HSPE1 mRNA |
CTD |
PMID:17917374 PMID:18544905 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Hyou1 |
hypoxia up-regulated 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HYOU1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 8:44,706,073...44,718,189
Ensembl chr 8:44,706,263...44,718,186
|
|
G |
Igf2r |
insulin-like growth factor 2 receptor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of IGF2R mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 1:47,979,109...48,067,501
Ensembl chr 1:47,979,109...48,067,501
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of IL1A mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of IL1B mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
increases expression |
ISO |
kojic acid results in increased expression of IL1RL1 mRNA |
CTD |
PMID:19000923 |
|
NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256
|
|
G |
Il22ra1 |
interleukin 22 receptor subunit alpha 1 |
increases expression |
ISO |
kojic acid results in increased expression of IL22RA1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:147,961,496...147,986,296
Ensembl chr 5:147,961,349...147,986,296
|
|
G |
Il6 |
interleukin 6 |
decreases expression |
ISO |
kojic acid results in decreased expression of IL6 protein |
CTD |
PMID:12727023 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il6st |
interleukin 6 cytokine family signal transducer |
decreases expression |
ISO |
kojic acid results in decreased expression of IL6ST mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:44,065,979...44,106,255
Ensembl chr 2:44,066,130...44,109,936
|
|
G |
Incenp |
inner centromere protein |
increases expression |
ISO |
kojic acid results in increased expression of INCENP mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:206,520,655...206,550,575
Ensembl chr 1:206,523,380...206,553,265
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
kojic acid results in increased expression of JUN mRNA |
CTD |
PMID:19000923 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kars1 |
lysyl-tRNA synthetase 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of KARS1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr19:39,957,846...39,976,837
Ensembl chr19:39,957,846...39,977,632
|
|
G |
Kcnab3 |
potassium voltage-gated channel subfamily A regulatory beta subunit 3 |
decreases expression |
ISO |
kojic acid results in decreased expression of KCNAB3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr10:54,047,830...54,056,401
Ensembl chr10:54,047,825...54,054,174
|
|
G |
Kctd17 |
potassium channel tetramerization domain containing 17 |
decreases expression |
ISO |
kojic acid results in decreased expression of KCTD17 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 7:109,979,060...110,009,091
Ensembl chr 7:109,979,060...110,008,927
|
|
G |
Kdm4d |
lysine demethylase 4D |
increases expression |
ISO |
kojic acid results in increased expression of KDM4D mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:11,279,756...11,304,920
Ensembl chr 8:11,268,859...11,305,290
|
|
G |
Klf5 |
KLF transcription factor 5 |
increases expression |
ISO |
kojic acid results in increased expression of KLF5 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445
|
|
G |
Klhl13 |
kelch-like family member 13 |
increases expression |
ISO |
kojic acid results in increased expression of KLHL13 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr X:113,942,309...114,107,299
Ensembl chr X:113,942,309...114,107,321
|
|
G |
Klkb1 |
kallikrein B1 |
decreases expression |
ISO |
kojic acid results in decreased expression of KLKB1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr16:46,958,634...46,982,054
Ensembl chr16:46,958,707...46,982,053
|
|
G |
Krt7 |
keratin 7 |
increases expression |
ISO |
kojic acid results in increased expression of KRT7 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 7:132,528,881...132,545,052
Ensembl chr 7:132,528,895...132,545,052
|
|
G |
Ktn1 |
kinectin 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of KTN1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr15:20,913,665...21,002,588
Ensembl chr15:20,914,642...21,002,578
|
|
G |
Larp7 |
La ribonucleoprotein 7, transcriptional regulator |
decreases expression |
ISO |
kojic acid results in decreased expression of LARP7 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:215,997,641...216,012,833
Ensembl chr 2:215,997,649...216,012,865
|
|
G |
Lilrb3 |
leukocyte immunoglobulin like receptor B3 |
decreases expression |
ISO |
kojic acid results in decreased expression of LILRB5 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:69,928,948...69,939,461
Ensembl chr 1:69,928,945...69,939,048
|
|
G |
Lrp6 |
LDL receptor related protein 6 |
decreases expression |
ISO |
kojic acid results in decreased expression of LRP6 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 4:167,269,856...167,400,364
Ensembl chr 4:167,270,353...167,400,497
|
|
G |
Lrrc4 |
leucine rich repeat containing 4 |
decreases expression |
ISO |
kojic acid results in decreased expression of LRRC4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 4:57,433,518...57,437,114
Ensembl chr 4:57,433,428...57,437,911
|
|
G |
Lrrc9 |
leucine rich repeat containing 9 |
increases expression |
ISO |
kojic acid results in increased expression of LRRC9 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 6:91,017,739...91,095,847
Ensembl chr 6:91,017,736...91,100,237
|
|
G |
Maea |
macrophage erythroblast attacher, E3 ubiquitin ligase |
increases expression |
ISO |
kojic acid results in increased expression of MAEA mRNA |
CTD |
PMID:16595896 |
|
NCBI chr14:77,357,261...77,390,683
Ensembl chr14:77,357,264...77,390,671
|
|
G |
Mafk |
MAF bZIP transcription factor K |
decreases expression |
ISO |
kojic acid results in decreased expression of MAFK mRNA |
CTD |
PMID:16595896 |
|
NCBI chr12:14,834,628...14,856,414
Ensembl chr12:14,833,984...14,837,048 Ensembl chr12:14,833,984...14,837,048
|
|
G |
Magec2 |
MAGE family member C2 |
increases expression |
ISO |
kojic acid results in increased expression of MAGEC2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr X:140,610,610...140,615,484
Ensembl chr X:140,606,825...140,615,471
|
|
G |
Maoa |
monoamine oxidase A |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of MAOA mRNA |
CTD |
PMID:18544905 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Maob |
monoamine oxidase B |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of MAOB mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of MAOB mRNA |
CTD |
PMID:18544905 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Map7d2 |
MAP7 domain containing 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of MAP7D2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr X:35,372,453...35,488,073
Ensembl chr X:35,372,700...35,488,091
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
ISO |
kojic acid results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:27586645 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation |
ISO |
kojic acid results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:27586645 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
decreases expression |
ISO |
kojic acid results in decreased expression of MAPK8 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mbnl1 |
muscleblind-like splicing regulator 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of MBNL1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:144,639,819...144,814,395
Ensembl chr 2:144,670,285...144,814,368
|
|
G |
Mc1r |
melanocortin 1 receptor |
decreases expression increases expression |
ISO |
kojic acid results in decreased expression of MC1R protein kojic acid results in increased expression of MC1R protein |
CTD |
PMID:23738040 PMID:27586645 |
|
NCBI chr19:51,452,448...51,455,375
Ensembl chr19:51,453,239...51,454,192
|
|
G |
Mdfi |
MyoD family inhibitor |
decreases expression |
ISO |
kojic acid results in decreased expression of MDFI mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 9:13,156,806...13,175,218
Ensembl chr 9:13,156,866...13,175,217
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of MDM2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Me3 |
malic enzyme 3 |
decreases expression |
ISO |
kojic acid results in decreased expression of ME3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:143,534,024...143,735,551
Ensembl chr 1:143,534,139...143,733,132
|
|
G |
Med14 |
mediator complex subunit 14 |
increases expression |
ISO |
kojic acid results in increased expression of MED14 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr X:10,036,749...10,127,910
Ensembl chr X:10,036,805...10,126,240
|
|
G |
Mex3b |
mex-3 RNA binding family member B |
increases expression |
ISO |
kojic acid results in increased expression of MEX3B mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:136,855,130...136,859,365
Ensembl chr 1:136,855,130...136,859,354
|
|
G |
Mfap4 |
microfibril associated protein 4 |
decreases expression |
ISO |
kojic acid results in decreased expression of MFAP4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr10:46,167,158...46,170,176
Ensembl chr10:46,167,217...46,170,155
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
multiple interactions |
EXP |
[kojic acid co-treated with Diethylnitrosamine] results in increased expression of MGMT mRNA; Ascorbic Acid inhibits the reaction [[kojic acid co-treated with Diethylnitrosamine] results in increased expression of MGMT mRNA] |
CTD |
PMID:18544905 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of MGST1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of MGST1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Midn |
midnolin |
decreases expression |
ISO |
kojic acid results in decreased expression of MIDN mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 7:9,548,100...9,559,605
Ensembl chr 7:9,549,650...9,559,752
|
|
G |
Mif |
macrophage migration inhibitory factor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of MIF mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of MIF mRNA |
CTD |
PMID:18544905 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504
|
|
G |
Mnd1 |
meiotic nuclear divisions 1 |
increases expression |
ISO |
kojic acid results in increased expression of GAJ mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:169,433,523...169,496,081
Ensembl chr 2:169,433,540...169,496,096
|
 | |